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ABSTRACT
This work describes the crystallographic studies of two enzymes and provides
mechanistic insights into their respective catalytic processes. The first study investigates the
molecular basis of the fructose-2,6-bisphosphatase reaction of the inducible isoform of the
bifunctional enzyme, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3). The
bifunctional enzyme is solely responsible for the cellular concentration of a regulator of glucose
metabolism, fructose-2,6-bisphosphate. PFKB3 was investigated using the crystal structures of
the enzyme in a phospho-enzyme intermediate state (PFKFB3-P•F-6-P), in a transition stateanalogous complex (PFKFB3•AlF4), and in a complex with pyrophosphate (PFKFB3•PPi). With
these structures, the structures of the Michaelis complex and the transition state were
extrapolated. Additionally the C-terminal domain (residues 440-446) was rearranged in
PFKFB3•PPi, implying that this domain plays a critical role in binding of substrate to, and
release of product from, the bisphosphatase catalytic pocket. These findings provide a new
insight into the understanding of the phosphoryl transfer reaction.
The second study investigates the molecular basis of the reaction catalyzed by the
pseudo-glycosyltransferase, VldE. VldE catalyzes non-glycosidic C-N coupling between an
unsaturated cyclitol and a saturated aminocyclitol with the conservation of the anomeric
configuration to form validoxylamine A 7´-phosphate, the biosynthetic precursor of the antibiotic
validamycin A. To study the molecular basis of its mechanism, the three-dimensional structures
of VldE from Streptomyces hygroscopicus subsp. limoneus was determined in apo form, in
complex with GDP, in complex with GDP and validoxylamine A 7´-phosphate, and in complex
with GDP and trehalose. The structures of VldE with the catalytic site in both an “open” and
“closed” conformation are also described. With these structures, the preferred binding of the
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guanine moiety by VldE, rather than the uracil moiety as seen in OtsA, could be explained. The
elucidation of the VldE structure in complex with the entirety of its products provides insight
into the internal return mechanism by which catalysis occurs with a net retention of the anomeric
configuration of the donated cyclitol.

x

CHAPTER 1: REVIEW OF LITERATURE, THE BIFUNCTIONAL ENZYME
Carbohydrate Metabolism
History of Metabolism
The term “metabolism”, which is derived from the Greek word “metabolē” for “change”
is defined as “the chemical changes in living cells by which energy is provided for vital
processes and activities and new material is assimilated” (Merriam-Webster Inc. 2005). In the
early 20th century, the term “metabolism” was synonymous with the term “nutrition” as both are
centered around the intake of nutrients as a sources of usable energy and precursors of biological
compounds (Bing 1971).
The scientific study of human metabolism is generally credited to originate with the
Italian physician Santorio Santorio. As recounted in his 1614 book Ars de Statica Medicina,
Santorio performed self-experimental studies on what he termed “insensible perspiration”
(Eknoyan 1999). Not until the 19th century works of Louis Pasteur, who demonstrated that the
fermentation of sugar by yeast was a biological process within its life cycle, and Friedrich
Wöhler, whose chemical synthesis of urea demonstrated that biological compounds could be
produced from non-organic chemicals, was it understood that the transformation of nutrients into
energy and biological compounds was not different from the general processes of chemistry
(Dubos 1951; Kinne-Saffran and Kinne 1999). With the discovery of enzymes by Eduard
Buchner at the beginning of the 20th century(Jaenicke 2007), biochemistry was born and
metabolism could now be thought of as a series of chemi-enzymatic reactions.
Glycolysis
Metabolism can be divided into two sets of processes, the catabolic processes in which
organic compounds are broken-down and the anabolic processes in which cellular components
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are synthesized. Glycolysis, also known as the Embden-Meyerhoff-Parnas pathway, is a
catabolic pathway through which there is an enzymatic degradation of carbohydrates into
pyruvate while energy is harvested in the forms of adenosine triphosphate (ATP) and reduced
nicotinamide adenine dinucleotide (NADH). In an aerobic environment, pyruvate is further
degraded into carbon dioxide and water by the citric acid cycle in order to send reducing
equivalents into oxidative phosphorylation. In human cells, the presence of an anaerobic
environment will cause the fermentation of pyruvate into lactic acid in order to regenerate
oxidized nicotinamide adenine dinucleotide (NAD+), which would allow the continuation of
glycolysis.
Although the glycolytic degradation of a single molecule of the carbohydrate glucose into
two pyruvates is mediated by a pathway of ten enzymes, three of these enzymatic reactions are
under a particularly stringent regulation (Figure 1.1). Because of the investment of a high
energy storage compound to the reaction in the form of ATP, the conversion of glucose to
glucose-6-phosphate by hexokinase is tightly regulated. Likewise, the investment of an ATP in
the conversion of fructose-6-phosphate (F6P) to fructose-1,6-bisphosphate (F-1,6-P2) by 6phosphofructose-1-kinase (PFK-1) gives need for tight regulation. The investment of second
ATP is a committal step and following this further investment glycolysis must proceed to
completion. The final step of glycolysis, the generation of pyruvate from phosphoenolpyruvate
(PEP) by pyruvate kinase, is also strictly controlled. Although the generation of glycolytic
products and product intermediates allow for cells to meet their energy demands while also
producing biosynthetic precursors for a series of biological compounds, glycolysis must be
regulated in order to balance the various metabolic processes within the cell. (McKee and
McKee 2009)
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Figure 1.1. Glycolysis and Gluconeogenesis. Shown are the key points of regulation of
glycolysis and gluconeogenesis within glucose metabolism.
3

Gluconeogenesis
The liver is responsible for the maintenance of blood glucose levels so that other tissues
such as muscle or brain may meet their individual energy demands. To fulfill this responsibility,
liver cells must be capable of regenerating glucose so that it can be introduced back into the
blood stream and transported to the various energy requiring tissues. One such method would be
the reformation of glucose by the enzymatic pathway known as gluconeogenesis.
Gluconeogenesis can generate glucose from metabolic precursors within the liver cells such as
pyruvate, or from lactate taken in from the blood stream via the Cori Cycle. Lactate can be
easily converted back to pyruvate by the enzyme lactate dehydrogenase.
Although similar to a reversal of the glycolytic pathway, gluconeogenesis must bypass
the three tightly regulated and irreversible enzymatic reactions of glycolysis through an
alternative set of enzymes (Figure 1.1). Pyruvate must be carboxylated by pyruvate carboxylase
before being decarboxlyated and phosphorylated by PEP carboxykinase during the regeneration
of phosphoenolpyruvate. Phosphoenolpyruvate will then be passed through a series of reversed
glycolytic reactions until fructose-1,6-bisphosphate is regenerated. The phosphofructose-1kinase reaction is again irreversible, and the dephosphorylated product, fructose-6-phosphate,
must be generated by fructose-1,6-bisphosphatase (F-1,6-P2ase). Gluconeogenesis would again
proceed through a reverse of glycolysis until glucose is regenerated by the dephosphorylation of
glucose-6-phosphate by glucose-6-phosphatase. Upon the completion of gluconeogenesis,
glucose is now available for release into the blood stream by the liver cells. Like the
corresponding reactions within glycolysis, these gluconeogenic reactions are under stringent
regulation, typically in a manner that is reciprocal to the regulation of glycolysis (McKee and
McKee 2009).
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The Discovery of Fructose-2,6-Bisphosphate and the Bifunctional Enzyme
As previously mentioned, phosphofructose-1-kinase (PFK-1) is an extremely important
regulatory enzyme within glycolysis. PFK-1 catalyzes the production of fructose-1,6bisphosphate from ATP and fructose-6-phosphate. The reaction, which is made important by the
investment of the second ATP to glycolysis, is considered the first committedstep to glycolysis.
Curiously, it was shown that at nearly physiological conditions including physiological
concentrations of its substrates and of its known effectors (F-1,6-P2, adenosine monophosphate
(AMP), and orthophosphate (Pi)), purified PFK-1 is nearly inactive in vitro (Reinhart and Lardy
1980). Because purified PFK-1 showed ample activity and because the activity of PFK-1 in
physiological conditions could be restored by reintroducing the contents of the low molecular
weight fractions obtained during the purification process, researchers realized that there must be
an additional activating factor lost during purification (Furuya and Uyeda 1980; Van
Schaftingen, Hue et al. 1980). Further investigation determined that this new low molecular
weight effector, whose cellular concentration is reduced by the introduction of glucagon or
epinephrine, works by relieving the inhibition of PFK-1 caused by the binding of a second ATP
molecule to an allosteric site on PFK-1 at cellular concentrations of ATP (Furuya and Uyeda
1980; Richards and Uyeda 1980).
Many preliminary observations regarding this stimulator were made. The cellular
concentration of the stimulator was increased by the introduction of glucose, and had a molecular
weight similar to F-1,6-P2. Because the stimulator was acid-labile and was capable of being
destroyed by alkaline phosphatase, it was assumed that the stimulator must be a phosphoric ester
(Van Schaftingen, Hue et al. 1980). Further analysis of the products generated by acid driven
hydrolysis showed that the stimulator consisted solely of F-6-P and Pi. Researchers suggested
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that the stimulator was most probably fructose-2,6-bisphosphate (F-2,6-P2) (Van Schaftingen,
Hue et al. 1980). This was confirmed using synthetic F-2,6-P2 to reproduce stimulation, and the
anomeric form of the stimulator was determined to be -D-fructose-2,6-bisphosphate (Figure
1.2A) (Van Schaftingen and Hers 1980; Furuya, Uyeda et al. 1981; Uyeda, Furuya et al. 1981).
With the discovery of a small molecular weight stimulator of a rate-limiting enzyme
within glycolysis, it was only natural to investigate what effect, if any, the compound had on
gluconeogenesis. Because PFK-1 and fructose-1,6-bisphosphatatase (F-1,6-P2ase) were already
known to share many effectors in a reciprocal manner, it was thought that F-1,6-P2ase was a
likely target of F-2,6-P2. Indeed, F-2,6-P2 was shown to be capable of inhibiting the enzymatic
activity of this key regulatory enzyme of gluconeogenesis (Pilkis, El-Maghrabi et al. 1981). As
both PFK-1 and F-1,6-P2ase would otherwise be involved in a futile cycle between F-1,6-P2
synthesis and degradation, discovery of F-2,6-P2 expanded the understanding of the cellular
coordination of glycolysis and gluconeogenesis (Uyeda, Furuya et al. 1982).
In 1981, Furuya and Uyeda released a publication in which they detailed the discovery of
a liver enzyme capable of synthesizing the PFK-1 stimulator, F-2,6-P2. This enzyme, 6phosphofructo-2-kinase (6-PF-2-Kase), catalyzes the reaction between D-fructose-6-phosphate
and ATP in the presence of magnesium in order to form D-fructose-2,6-bisphosphate and
adenosine diphosphate (ADP) (Figure 1.2B) (Furuya and Uyeda 1981). It was determined that
the activity of 6-PF-2-Kase was sensitive to covalent modification by phosphorylation.
Specifically, the enzyme was inactivated by phosphorylation by cyclic-AMP dependent kinase
and activated by dephosphorylation by phosphatase (Van Schaftingen, Davies et al. 1981;
Furuya, Yokoyama et al. 1982).
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Figure 1.2. Fructose-2,6-Bisphosphate. Shown is (A) the chemical structure of fructose-2,6bisphosphate, an effector of glycolytic flux, and (B) the enzymatic reactions responsible for the
synthesis and degradation of this effector.
Within a year of the discovery of 6-PF-2-Kase, an enzyme responsible for the
degradation of F-2,6-P2 into F-6-P and Pi was also found within liver extracts (Figure 1.2B) (Elmaghrabi, Claus et al. 1982; Furuya, Yokoyama et al. 1982). Inversely to 6-PF-2-Kase, the
hydrolytic activity of this new enzyme, fructose-2,6-bisphosphatase (F-2,6-P2ase), was activated
by cyclic-AMP dependent kinase and inactivated by glucagon and epinephrine (Furuya,
Yokoyama et al. 1982; Richards, Yokoyama et al. 1982). Strangely, 6-PF-2-Kase and F-2,6P2ase coeluted from phosphocellulose columns, were of similar molecular weights, and consisted
of similarly sized catalytic units. It did not take long for researchers to realize that these two
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enzymes were in fact a single bifunctional enzyme with opposing catalytic functions and
reciprocal methods of regulation (El-maghrabi, Claus et al. 1982; Pilkis, Chrisman et al. 1983).
Two Functional Folds
Opposing Reactions
The bifunctional enzyme, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase, is
solely responsible for the cellular concentration of the glycolytic regulator, fructose-2,6bisphosphate. It fulfills its role by concertedly synthesizing and degrading this effector.
Although this single polypeptide catalyzes both opposing reactions, the reactions do not
necessarily proceed through analogous mechanisms (Kim, Cavalier et al. 2007). The
phosphotransferase activity of the N-terminal domain, which uses ATP as a source for the highenergy phosphoester bond, is mediated by a fold belonging to the P-loop NTPase superfamily
(Hasemann, Istvan et al. 1996; Leipe, Koonin et al. 2003). Conversely, the hydrolytic activity of
the C-terminal domain is mediated by a fold belonging to the histidine phosphatase superfamily
which does not regenerate ATP but instead yields orthophosphate (Hasemann, Istvan et al. 1996;
Rigden 2008).
Histidine Phosphatases
The histidine phosphatase superfamily can be divided into two evolutionarily related
branches, the phosphoglycerate mutase family which includes fructose-2,6-bisphosphatase and
the acid phosphatase family which also includes the phytases (Rigden 2008). Although the
highest observed percentage identity between the two branches of enzymes is only 18%, there is
an unambiguous evolutionary relationship between the sequences of both branch members as
was further illustrated upon the solving of the first crystal structure of the first acid phosphatase
family enzyme in 1993 (Schneider, Lindqvist et al. 1993; Rigden 2008). Members of both
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branches share a RHG motif near the beginning of the fold, whose histidine is known to be
phosphorylated during catalysis (Bazan, Fletterick et al. 1989). It should be noted that there is a
clear distinction between the subcellular localization of the enzyme members of the two
branches. While the phosphoglycerate mutase family enzymes are generally found in the
cytoplasm or the nucleus, acid phosphatase enzymes enter into the secretory pathway and are
found in the endoplasmic reticulum, the cell surface, periplasm, cell wall, or secretions (Rigden
2008). The Pfam database (http://pfam.sanger.ac.uk/) classifies over 15,000 sequences within
the phosphoglycerate mutase family and over 2,600 sequences within the acid phosphatase
family with both families having extensive prokaryotic and eukaryotic representatives.
However, there are no acid phosphatase family members and only 86 phosphoglycerate mutase
family members found within archaea (as of June 16, 2012) (Punta, Coggill et al. 2012).
The histidine phosphatases are diverse in function and are known to play roles in many
metabolic pathways. Examples would include the cofactor-dependent phosphoglycerate mutase
(dPGM) within glycolysis/gluconeogenesis, adenosylcobalamin-5´-P phosphatase (CobC) in
vitamin B12 biosynthesis (Zayas and Escalante-Semerena 2007), 5´phosphoribostamycinphosphatase (NeoP) within neomycin biosynthesis (Huang, Haydock et al.
2005; Kudo and Eguchi 2009), and the fungal phosphate scavenging enzymes such as nucleotide
phosphatase (Pho5p) and phytase (Irving and Cosgrove 1972; Kennedy, Pillus et al. 2005).
Histidine phosphatases are also known to play roles in signaling/regulation. For example,
fructose-2,6-bisphosphatase degrades a small molecule responsible for the regulation of
glycolytic flux while the phosphomutase (PMU1) regulates the concentration of a small molecule
influencing transcription of adenine synthesis genes in yeast, and the eukaryotic multiple inositol
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polyphosphate phosphatase 1(Minpp1) regulates the concentrations of other signaling molecules
(Chi, Yang et al. 2000; Rebora, Laloo et al. 2005; Michels and Rigden 2006).
The catalytic mechanism of the histidine phosphatases works through the
phosphorylation of a histidine residue to form a phospho-enzyme intermediate state followed by
its dephosphorylation (Figure 1.3). Neighboring residues, in particular a second histidine and
two arginines form a phosphate pocket and stay in contact with the phosphate oxygens before
during and after the linear transfer of phosphate. The conserved RHG motif of histidine
phosphatases is completed by a glycine residue (sometimes alanine) which packs closely to the
protein core and whose carbonyl makes an important hydrogen bond with the phosphorylated
histidine side-chain placing the group in an appropriate position for catalysis. There is also a
conserved L[S/T]XXG motif in the second layer behind the catalytic site which adds to the
maintenance of the histidine conformation which is extremely important for catalysis (Rigden
2008).

Figure 1.3. The catalytic mechanism of histidine phosphatases. Shown is the prototypical
histidine phosphatase catalyzed reaction with a phospho-histidine intermediate step.
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P-loop Kinases
Found within prokaryotes, eukaryotes and archaea, the P-loop NTPase superfamily is the
most abundant and diverse of several distinct nucleotide triphosphate (NTP)-binding folds and
was estimated to comprise 10-18% of the predicted gene products of the sequenced prokaryotic
and eukaryotic genomes (Koonin, Wolf et al. 2000; Leipe, Koonin et al. 2003). The P-loop
NTPases are characterized by Walker A (P-loop) and B motifs responsible for the binding of the
and  phosphates of the NTP as well as a Mg2+ cation (Figure 1.4). The Walker A motif adopts
a GXXXXGK[ST] sequence pattern while the Walker B motif (hhhhD, where h is a hydrophobic
residue) contains a conserved aspartate (occasionally glutamate) which coordinates the Mg2+
with the  and  phosphates. This conserved aspartate also interacts with the conserved
serine/threonine of the Walker A motif which properly positions the two phosphate-binding
domains (Walker, Saraste et al. 1982).
Amongst the P-loop NTPases are the P-loop kinases which transfer the -phosphate of the
NTP to a wide range of substrates. Outside of P-loop folds, kinases have evolved independently
within a number of folds such as Rossman, RRM-like, ribonuclease H, and TIM / barrel folds
(Cheek, Zhang et al. 2002). Amongst the best characterized P-loop kinases are the nucleotide
kinases such as adenylate kinase (AK) and the small molecule kinases such as 6-phosphofructo2-kinase and shikimate kinase. Shikimate kinase transfers the terminal phosphate of ATP to the
3-hydroxyl of shikimic acid and is part of the biosynthesis of chorismic acid, a precursor for
aromatic compounds essential to plants and micro-organisms (Krell, Coggins et al. 1998). Of
course, 6-phosphofructo-2-kinase is responsible for the synthesis of a regulator of glucose
metabolism, fructose-2,6-bisphosphate (Kim, Cavalier et al. 2007). Adenylate kinase catalyzes
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Figure 1.4. P-loop NTPases. Shown is the typical binding of a nucleotide triphosphate by the
Walker A and B motifs of P-loop NTPases.
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the transfer of a phosphate from ATP to AMP which links AMP to the ADP/ATP
equilibrium of the cell (Muller and Schulz 1992).
Amongst the P-loop NTPases, the P-loop kinases are most similar to the GTPases which
include the enzymes Ras and the elongation factor Tu (EF-Tu) (Leipe, Wolf et al. 2002; Leipe,
Koonin et al. 2003). However, P-loop kinases are clearly discernible by the presence of a mostly
helical LID module. The LID module contributes an arginine residue (asparagine in the case of
6-PF-2-Kase), which interacts with the nucleotide base, as well as a second conserved basic
residue (arginine or lysine), which is thought to stabilize the transition state by neutralizing the
developing negative charge on the - oxygen atom (Leipe, Koonin et al. 2003).
Upon the elucidation of the crystallographic structure of 6-PF-2-Kase in 1996, a
structural relationship between 6-PF-2-Kase, the nucleotide kinases, and the GTPases was
immediately apparent (Hasemann, Istvan et al. 1996). The structural similarity between the
catalytic sites of 6-PF-2-Kase and adenylate kinase supported the recent rejection of a proposed
6-PF-2-Kase mechanism of catalysis operating through a general base which would activate the
sugar hydroxyl group to potentiate its nucleophilic attack of the -phosphate of ATP. This
rejected mechanism was based on the assumption that the phosphorylation of the fructose-6phosphate at the 2-hydroxyl group by 6-PF-2-Kase would proceed through a mechanism similar
to the phosphorylation of the 1-hydroxyl group by 6-phosphofructose-1-kinase. 6-PF-2-Kase,
like adenylate kinase, lacks such a nucleophile. Instead, 6-PF-2-Kase is thought to only mediate
a transition state stabilization (Hasemann, Istvan et al. 1996). The P-loop kinases do not contain
a traceable ancestral nucleophile, although individual P-loop kinases have independently
acquired one on multiple occasions (Leipe, Koonin et al. 2003).
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The Tissue Specific Isoforms of the Bifunctional Enzyme
Conserved Structure
In 1996, the first structural characterization of the bifunctional enzyme, in its entirety,
was performed using x-ray crystallographic techniques on the testis isoenzyme (Hasemann,
Istvan et al. 1996). Since, the crystallographic structures of the liver and inducible isoforms have
also been elucidated (Lee, Li et al. 2003; Kim, Manes et al. 2006). The biologically active unit of
the bifunctional enzyme is a homodimer (Figure 1.5). Each monomer consists of two clearly
divided catalytic domains. The N-terminal half of the polypeptide forms the kinase functional
domain, while the C-terminal half forms the bisphosphatase functional domain (Hasemann,
Istvan et al. 1996). All tissue-specific isoforms of the bifunctional enzyme, whose structures
have been elucidated, tightly conserve the fold of the two catalytic domains. The main points of
divergence are the C- and N- terminal segments (Hasemann, Istvan et al. 1996; Lee, Li et al.
2003; Kim, Manes et al. 2006). As described elsewhere within this document, these terminal
segments encode phosphorylation sites which allow for regulation of the cellular concentrations
of F-2,6-P2 by fluctuating the balance of kinase and bisphosphatase activities (Figure 1.6).
The N-terminal catalytic domain (6-PF-2-K) consists of a six stranded -sheet
surrounded by seven-helices. Within this fold, the binding of ATP is facilitated by a Walker A
motif (Gly-X-X-Gly-X-Gly-Lys-Thr). The adenosine moiety is stacked within non-polar
residues. A Walker B motif (Z-Z-Z-Z-Asp, where Z is any hydrophobic residue) orients the
octahedral Mg2+ ion coordination between the protein and the - and -phosphates of ATP
(Hasemann, Istvan et al. 1996). These motifs are commonly associated with the adenylate kinase
(AK), Ras, and EF-Tu families of nucleotide binding proteins (Walker, Saraste et al. 1982; Traut
1994). F-6-P and ATP binding loops conform around the substrates to exclude water from the
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Figure 1.5. The crystal structures of the bifunctional enzyme. Shown are ribbon diagrams
representing the crystal structures of the tissue-specific isoforms of 6-phosphofructo-2kinase/fructose-2,6-bisphosphatase.
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Figure 1.6. Covalent modification of the bifunctional enzyme. Shown are the
phosphorylation sites unique to each tissue-specific isoform of 6-phosphofructo-2kinase/fructose-2,6-bisphosphatase.
active site (Hasemann, Istvan et al. 1996). The substrates ATP and F-6-P are oriented so that
there is a strong direct substrate-substrate interaction between the -phosphate of ATP and the
O2 oxygen of F-6-P. Upon the substrate-assisted deprotonation of the O2 oxygen, F-6-P can
perform a nucleophilic attack on the -phosphate of ATP (Kim, Cavalier et al. 2007). This is
followed by an “in-line” transfer of phosphate accompanied with the inversion of the phosphate
stereochemistry (Kitajima, Sakakibara et al. 1984; Lahiri, Zhang et al. 2003; Klahn, Rosta et al.
2006; Wittinghofer 2006). The Mg2+ ion bound by the Walker B motif holds the-phosphate of
ATP in the proper position for catalysis (Figure 1.7) (Vertommen, Bertrand et al. 1996).
The C-terminal catalytic domain (F-2,6-P2ase) also consists of a central -sheet with
surrounding -helices. An additional subdomain of two helices contributes residues to substrate
binding (Hasemann, Istvan et al. 1996). F-2,6-P2ase belongs to the acid phosphatases and
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Figure 1. 7. The kinase reaction. Shown is reaction catalyzing the synthesis of fructose-2,6bisphosphate by the kinase domain of phosphofructo-2-kinase/fructose-2,6-bisphosphatase.
phosphoglycerate mutase family of enzymes (Bodansky 1972; Fothergillgilmore and Watson
1989). These enzymes worked through a shared mechanism involving a covalent phosphorhistidine intermediate within a conserved sequence motif (Z-X-Arg-His-Gly- Glu/Gln-X-X-XAsn, where Z is a hydrophobic residue) (Rose 1970; Vanetten and Hickey 1977; Pilkis,
Walderhaug et al. 1983).
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The active homodimer assembles in a head-to-head manner. The N-terminal kinase
domains interact in a manner by which the six stranded -sheet of each is oriented to form a
single twelve stranded -sheet. The kinase domains scarcely interact at all (Hasemann, Istvan et
al. 1996).
Liver
To account for the metabolic demands of the individual tissues, there are four tissuespecific isoforms of the bifunctional enzyme (also known as phosphofructo-2-kinase/fructose2,6-bisphosphatase or PFKFB). The first of which is the liver isoform (PFKFB1), which is
encoded by the gene, pfkfb1 (Algaier and Uyeda 1988). A splice variant of the pfkfb1 gene is also
responsible for the encoding of the skeletal form of the bifunctional enzyme, which has an
alternative N-terminus (Darville, Crepin et al. 1989).
PFKFB1 contains one phosphorylation site near the N-terminus (Figure 1.7). In response
to glucagon, cAMP-dependent protein kinase (PKA) is stimulated, and PFKFB1is
phosphorylated at Ser32. (Murray, Elmaghrabi et al. 1984). This results in an inactivation of the
6-PF2-K activity in concert with an activation of the F-2,6-P2ase activity (Van Schaftingen,
Davies et al. 1981; El-maghrabi, Claus et al. 1982; Van Schaftingen, Davies et al. 1982;
Sakakibara, Kitajima et al. 1984). The kinase:bisphosphatase ratio of catalysis shifts from 1.4 to
0.2, a shift from a predominant F-2,6-P2 synthesis to a predominant F-2,6-P2 degradation (ElMaghrabi, Noto et al. 2001). The resulting decrease in F-2,6-P2 concentration will slow
glycolysis while stimulating gluconeogenesis within the liver. Because of the alternative
splicing, the skeletal isoform lacks this phosphorylation site, and its activity is not subject to
phosphorylation by PKA (Crepin, Darville et al. 1989). By comparing the skeletal enzyme to
the liver form, the role of the N-terminus is regulation becomes even more apparent. The
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skeletal enzyme has a kinase:bisphosphatase catalytic ratio of only 0.04, which is analogous to
the net direction of F-2-6-P2 degradation seen in the phosphorylated liver isoform. As skeletal
tissue is highly glycolytic, the isoform is well suited to the metabolism of the tissue. The lack of
a regulatory site leaves the net direction of catalysis by the skeletal form solely dependent of the
concentration of F-6-P (El-Maghrabi, Noto et al. 2001).
Heart
In 1985, the gene product of pfkfb2 was discovered (Rider, Foret et al. 1985). The heart
isoform (PFKFB2) shares highly conserved catalytic domains with the liver isoform. The
primary differences between the isoforms are at the C- and N-termini (Figure 1.7) (Darville,
Chikri et al. 1991). PFKFB2 does not contain a single phosphorylation site on the N-terminus
but instead two sites on the C-terminus. In opposition to PFKFB1, phosphorylation of PFKFB2
at these sites by PKA and insulin-stimulated protein kinase leads to an activation of kinase
activity and an inactivation of the bisphosphatase activity (Deprez, Vertommen et al. 1997).
Testes
In 1991, the gene product of pfkfb4 was cloned and characterized (Sakata, Abe et al.
1991). The testes isoform (PFKFB4) also shares highly conserved catalytic domains with the
liver and isoform. Again, it is the C- and N-termini which diverge from the other isoforms. Like
the skeletal isoenzyme, PFKFB4 does not contain any sites of phosphorylation and is not subject
to regulation by PKA (Figure 1.7). Testes tissues are also highly glycolytic and the kinetics of
the testes isoform of the bifunctional enzyme suggest that is an intermediate between the muscle
and liver forms which has a higher kinase:bisphosphatase ratio and is active at lower substrate
concentrations (El-Maghrabi, Noto et al. 2001).
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Inducible
The gene product of pfkfb3 is a PFKFB isoenzyme (PFKFB3) that is ubiquitously
expressed (Manzano, Rosa et al. 1998). PFKFB3 is the same isoenzyme that been previously
reported to be contained within the tissues of the brain, placenta, and pancreatic -islets.
(Ventura, Rosa et al. 1992; Sakakibara, Okudaira et al. 1999; El-Maghrabi, Noto et al. 2001). As
PFKFB3 expression is stimulated by hypoxia, it is often referred to as the inducible isoform
(Minchenko, Leshchinsky et al. 2002). PFKFB3, which has the highest kinase:bisphosphatase
activity ratio, allows for elevated F-2,6-P2 levels, and thus an increase in glycolytic flux. In fact,
the bisphosphatase domain of the inducible isoform is nearly inactive (Sakakibara, Okudaira et
al. 1999). PFKFB3 has been linked to the elevated glycolytic activity within cancer cells
(Chesney, Mitchell et al. 1999). The inducible isoform does contain a single site for
phosphorylation by PKA (Figure 1.7). Phosphorylation further elevates the
kinase:bisphosphatase activity ratio of PFKFB3 (Sakakibara, Kato et al. 1997). The 2006
structure of PFKFB3 described the N-terminus exists as a -hairpin motif which makes contact
with the bisphosphatase domain (Figure 1.5B) (Kim, Manes et al. 2006). This can help to
explain the regulatory effect of the N-terminus of the C-terminal bisphosphatase domain and vice
versa.
PFKFB3 and the Warburg Effect
The Glycolytic Phenotype of Cancer
In order to proceed through the processes of uncontrolled cell division and proliferation,
cancer cells uptake glucose at levels that are in far excess of what is needed to meet energetic
demands (Bauer, Harris et al. 2004; DeBerardinis, Lum et al. 2008). Curiously, cancer cells
continue with a high level of glucose uptake and glycolysis despite the availability of O2 (aerobic
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glycolysis) (Gatenby and Gillies 2004; Moreno-Sanchez, Rodriguez-Enriquez et al. 2007). This
phenomena was first described by Dr. Otto Warburg in 1956, and thus it is often recognized as
the “Warburg Effect” (Warburg 1956). The rapid uptake of glucose is the basis by which the
glucose analog, 18F-fluorodeoxyglucose, is used as a tracer to visualize the presence of tumors
through positron emission topography (Wechalekar, Sharma et al. 2005).
High levels of glycolytic metabolism do provide a series of advantages to cancer cells.
Firstly, glycolysis generates the necessary precursors for the de novo synthesis of nucleotides and
lipids which are required in large quantities during the stages of uncontrolled division and
proliferation. (Bui and Thompson 2006). Besides being provided with ample energy and
biosynthetic building blocks, cancer cells suppress healthy neighboring cells by consuming the
majority of diffusible substrates (Pfeiffer, Schuster et al. 2001). Furthermore, accelerated
glycolytic processes causes a drop in the pH of the surrounding tissue which can initiate
apoptosis in neighboring cells with a functional p53 (Williams, Collard et al. 1999). Despite the
advantages, it must be noted that the Warburg Effect makes the cells dependent on the
availability of substrates (Gatenby and Gillies 2004).
PFKFB3 and Cancer
In the absence of stimulator, PFK-1 is inactive in physiological conditions, and tumor
cells do contain inhibitory levels of ATP. It is thought that high levels of F-2,6-P2 may
contribute to aerobic glycolysis within tumor cells (Hue and Rousseau 1993). Studies of
established cancer cell lines have indicated that F-2,6-P2 concentrations are often elevated (Hue
and Rousseau 1993). In the case of chronic lymphocytic leukemia cells, the concentration of F2,6-P2 is the same as in control lymphocytes, but the sensitivity of PFK-1 for F-2,6-P2 is about
one-hundred times greater (Colomer, Vivescorrons et al. 1987).

21

Due to the reports concerning F-2,6-P2 within cancer biology, an analysis of the
bifunctional enzyme’s activity within cancer cells was initiated. These studies showed that
bifunctional enzyme taken from cancer cells was seemingly devoid of F-2,6-P2ase activity
(Loiseau, Rider et al. 1988). This would hint to presence of the inducible isoform of the
bifunctional enzyme. Indeed, later studies have shown that PFKFB3 mRNA is expressed in
breast cancer, leukemia, and adenocarcinoma (Hamilton, Callaghan et al. 1997; Chesney,
Mitchell et al. 1999). PFKFB3 was later found to be neoplastic requirement for transformation
by the oncogene, ras (Telang, Yalcin et al. 2006). The suppression of PFKFB3 through the use
of silencing siRNA resulted in the reduction of F-2,6-P2 concentrations and glycolytic activity, as
well as a reduction in cancer cell viability (Calvo, Bartrons et al. 2006).
The Hypoxia-Inducible Transcription Factor HIF-1
An explanation for the expression of PFKFB3 in cancer cells can be possibly be
attributed to the hypoxia-inducible transcription factor HIF-1. HIF-1 is the primary regulator of
the hypoxic response in animal cells. Particularly, HIF-1 is responsible for a switch in form of
energy metabolism from oxidative phosphorylation to glycolysis. HIF-1 is frequently expressed
at high levels in cancer cells, and in turn, induces the expression of genes involved in
erythropoiesis, angiogenesis, and anaerobic metabolism (Caro 2001; Maxwell, Pugh et al. 2001;
Brahimi-Horn and Pouyssegur 2006; Semenza 2006). The activation of HIF-1 can be triggered
by a series of growth factors and oncogenes (Thornton, Lane et al. 2000; Semenza 2002; Zhou
and Brune 2006).
HIF-1 is a hetero-dimeric transcription factor formed by an -subunit, whose expression
is dependent of the availability of O2, and a -unit, which is constitutively expressed (Semenza
2002). In the absence of O2, the -subunit is no longer subject to degradation via the ubiquitin-
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proteasome system (Huang, Arany et al. 1996; Salceda and Caro 1997). The functional
heterodimer works by binding hypoxia response elements within the promoters of the targeted
genes (Caro 2001; Maxwell, Pugh et al. 2001). In such a manner, HIF-1 suppresses the Krebs
cycle and respiration by inducing transcription of pyruvate dehydrogenase kinase 1 (PDK1).
PKD1 reduces the amount of pyruvate entering the Krebs cycle by inactivating pyruvate
dehydrogenase though phosphorylation (Kim, Tchernyshyov et al. 2006). This also reduces
oxygen consumption in the cell (Papandreou, Cairns et al. 2006). Also included amongst the
transcriptional targets of HIF-1 are glucose transporters and glycolytic enzymes including
PFKFB3 (Dang and Semenza 1999; Minchenko, Leshchinsky et al. 2002; Obach, NavarroSabate et al. 2004). Indeed, PFKFB3 is expressed in many cancer cells (Atsumi, Chesney et al.
2002; Calvo, Bartrons et al. 2006; Telang, Yalcin et al. 2006).
PFKFB3 as a Therapeutic Target
Cancer cells are dependent on glycolysis as metabolic source of energy, and it has been
observed that cancer cells are sensitive to glucose deprivation. For these reasons, selective
inhibition of glycolysis within cancer cells has become a therapeutic target (Shim, Chun et al.
1998). Inhibitors of the glycolytic enzyme, hexokinase, have been successfully shown to
suppress tumor growth (Xu, Pelicano et al. 2005; Pelicano, Martin et al. 2006). The studies,
which show that siRNA suppression of PFKFB3 results in a reduction of cancer cell viability
(Calvo, Bartrons et al. 2006), has led to attempts to generate selective inhibitors for the inducible
isoform of the bifunctional enzyme. One group was able to identify a novel PFKFB3 inhibitor
through in silico techniques, 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO). 3PO is
capable of reducing cellular concentrations of F-2,6-P2 and glycolytic flux in transformed cells.
3PO is also selectively cytostatic to ras-transformed cells, and has been shown to suppress tumor
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growth in breast adenocarcinoma, leukemia, and lung adenocarcinoma cells in vivo (Clem,
Telang et al. 2008). A second group has also identified two more PFKFB3 inhibitors, N4A (5, 6,
7, 8-tetrahydroxy-2-(4-hydroxyphenyl) chromen-4-one) and YN1 (7, 8-dihydroxy-3-(4hydroxyphenyl) chromen-4-one), using in silico techniques(Seo, Kim et al. 2011). These
inhibitors as well were capable of reducing cellular F-2,6-P2 concentrations and glycolytic flux in
cancer cell lines, which resulted in a suppression of tumor growth and massive cell death.
Additionally, the inhibitors were found within the x-ray crystallographic structure of PFKFB3,
which will eventually lead to a foundation for structure assisted optimization and development of
novel PFKFB3 inhibitors (Seo, Kim et al. 2011).
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CHAPTER 2: MOLECULAR BASIS OF THE FRUCTOSE-2,6-BISPHOSPHATASE
REACTION OF PFKFB3: TRANSITION STATE AND THE C-TERMINAL
FUNCTION*
Introduction
Fructose-2,6-bisphosphate (F-2,6-P2) is known to be the most potent allosteric activator
of the rate-limiting enzyme in glycolysis, 6-phosphofructose-1-kinase (PFK-1), as well as an
inhibitor of the gluconeogenic enzyme fructose-1,6-bisphosphatase (F-1,6-P2ase). As such, this
small signaling molecule allows for switching between the two pathways of glucose metabolism
within the liver, playing a crucial role in maintaining glucose homeostasis in mammalian bodies
and controlling the rates of glycolysis in other tissues(Claus, El-Maghrabi et al. 1984). The
concentration of F-2,6-P2 is regulated by the bifunctional enzyme, 6-phosphofructo-2kinase/fructose-2,6-bisphosphatase (PFKFB). The N-terminal half of the enzyme subunit (6phosphofructo-2-kinase domain) catalyzes the synthesis of F-2,6-P2, using fructose-6-phosphate
(F-6-P) and adenosine 5'-triphosphate (ATP) as substrates (Figure 2.1A). Conversely, the Cterminal half (fructose-2,6-bisphosphatase domain) is responsible for the hydrolytic degradation
of F-2,6-P2 into F-6-P and inorganic phosphate (Pi). These two mutually opposing catalytic
activities are controlled by different mechanisms such that either activity is predominant in a
given physiological condition. Ultimately, the PFKFB control of F-2,6-P2
production/degradation controls the rate of glucose metabolism (Kountz, Freeman et al. 1988).
In order to optimize the regulation of F-2,6-P2 in a tissue-specific manner, there exist four
PFKFB tissue-specific isoforms each encoded by separate genes pfkfb1-4. They are liver,
PFKFB1; heart, PFKFB2; testis, PFKFB4; and inducible forms, PFKFB3 (Algaier and Uyeda
*

This chapter first appeared as “Cavalier, M.C.; S.-G. Kim, et al. (2012) Molecular
basis of the Fructose-2,6-bisphosphatase reaction of PFKFB3: Transition state and the
C-terminal function. Proteins 80, 1143-53”. The “Material” was reproduced with
permission of John Wiley & Sons, Inc. ©2011 Wiley Periodicals, Inc.
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1988; Sakai, Kato et al. 1996; Heine-Suner, Diaz-Guillen et al. 1998; Manzano, Rosa et al.
1998). These isoforms share highly conserved core catalytic domains (85%) (Figure 2.2), but
differ greatly in their kinetic properties and responses to regulatory signals. These differences
are mostly due to highly divergent N- and C-terminal regulatory domains(Kurland, Li et al.
1993; Lin, Kurland et al. 1994; Kurland, Chapman et al. 2000); however, a few but significant
sequence differences in the catalytic domains that constitute the secondary residue shells
surrounding the active sites also contribute to the kinetic differences(El-Maghrabi, Noto et al.
2001). Differences in the structure/function relationships between these isoforms have been

Figure 2.1. Overall folding of PFKFB3 and sites of ligand binding. All figures, unless
otherwise noted, were constructed using PyMOL (The PyMOL Molecular Graphics System,
Version 1.2r3pre, Schrödinger, LLC.). (A) The overall fold of the monomeric PFKFB3 is
represented in a ribbon diagram. The N-terminal kinase domain (6-PF-2-k) is shaded red while
the C-terminal bisphosphatase domain (F-2,6-P2ase) is shaded blue. Each active site location can
be discerned by the bound ligands. The ADP and F-2,6-P2 are within the kinase active site
while F-6-P and a covalently attached phosphate are within the bisphosphatase active site.
Molecules of interest are represented in stick models. (B) To compare the organization of the
C-termini, the bisphosphatase domains of the inducible (blue) (PDB ID: 2AXN) (Kim, Manes et
al. 2006), testes (yellow) (PDB ID: 1BIF) (Hasemann, Istvan et al. 1996), and liver (red) (PDB
ID: 1K6M) (Lee, Li et al. 2003) isoforms have been superimposed. The folding patterns are
represented by a tracing of the C-alphas.
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Figure 2.2. Sequence alignment of PFKFB. Shown are the sequence alignments of the
bisphosphatase domain of the four PFKFB isoforms. Residue numbering coincides with the
residues of PFKFB3. Residues involved in catalysis, substrate binding, and the initiation of the
conformational change are emphasized with boxes. Asterisks mark residues of interest that are
conserved in all isoforms except for PFKFB3.

addressed using the available crystal structures of PFKFB1, PFKFB3, and PFKFB4(Hasemann,
Istvan et al. 1996; Lee, Li et al. 2003; Kim, Manes et al. 2006). For a more complete
comparison, the structure of PFKFB2 needs to be determined.
Unlike the other isoforms, PFKFB3 is ubiquitously expressed upon the onset of
hypoxia(Minchenko, Leshchinsky et al. 2002; Minchenko, Opentanova et al. 2003) and has been
shown to be identical to the isoforms isolated from placenta, pancreatic -islet, and
brain(Sakakibara, Okudaira et al. 1999; Goren, Manzano et al. 2000; El-Maghrabi, Noto et al.
2001). PFKFB3 has a uniquely large 6-phosphofructo-2-kinase to fructose-2,6-bisphosphatase
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activity ratio compared to other isoforms. This isoform, which has a native activity ratio of
roughly 700 fold kinase-to-phosphatase activity, dramatically increases up to 3000 upon
phosphorylation of Ser460 by protein kinase A (PKA) or AMP-dependent protein kinase
(AMPPK)(Okamura and Sakakibara 1998; Marsin, Bertrand et al. 2000; Atsumi, Chesney et al.
2002; Marsin, Bouzin et al. 2002; Manes and El-Maghrabi 2005). Recent studies suggest that
this form is a causative molecule of highly elevated levels glycolysis in tumor cells, a
phenomenon known as the ‘Warburg effect’(Warburg 1956). Thus, it has also been suggested
that PFKFB3 may serve as a promising new target for future cancer chemotherapy(Hirata,
Watanabe et al. 2000; Chesney, Telang et al. 2005). Consequently, an intensive study to
investigate the structure/function relationship of PFKFB3 has been performed, and the catalytic
mechanism of the kinase reaction for the synthesis of F-2,6-P2 was recently hypothesized from
the structural evidence(Kim, Manes et al. 2006; Kim, Cavalier et al. 2007).
The low bisphosphatase activity of PFKFB3, which is lower than that of other isoforms
by an order of magnitude(Manes and El-Maghrabi 2005), provides a unique opportunity for the
study of the bisphosphatase reaction. In the present study, we determined an improved crystal
structure of the PFKFB3 phospho-enzyme intermediate state (PFKFB3-P•F-6-P) trapped during
the bisphosphatase reaction; PFKFB3 complexed with aluminum tetrafluoride (AlF4) within the
bisphosphatase catalytic pocket (PFKFB3•AlF4), which mimics the transition state of a
phosphoryl transfer; and PFKFB3 complexed with inorganic pyrophosphate (PFKFB3•PPi) in
which a novel conformation of C-terminus residues 440-446 was observed. From these
structures, we were able to deduce all the structures necessary for understanding of this reaction,
namely, the Michaelis complex state and the transition states. This study provided a new insight
into the catalytic mechanism of this histidine phosphatase and the results are discussed here.
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Results
Overall Structure
In this study, three models (PFKFB3-P•F-6-P, PFKFB3•AlF4, and PFKFB3•PPi) which in
concert detail the enzyme state through substrate binding, catalysis, and product release during
the bisphosphatase reaction (Figure 2.3) are being introduced. The global conformation of these
models including crystal contacts, the dimeric interface, and domain/domain interactions are not
significantly affected by the liganding conditions varied in this experiment. As detailed in
previous structural studies, a subunit of the active dimer of PFKFB3 is comprised of a single
polypeptide encompassing two catalytic domains. (Figure 2.1A) In each complex, N-terminal
residues 4 through 15 form a β-hairpin structure to make contacts with bisphosphatase domain at
the area where the residues involved in binding of both product and substrate are concentrated.
In this way, the self-regulatory effect of the N-terminus on F-2,6-P2ase activity(Kim, Manes et
al. 2006) is not affected by experimentally varied liganding. Unlike the N-terminus, the Cterminus residues (460-520) remain disordered and have not yet been elucidated. The only
apparent conformational change observed occurs at C-terminus residues 440-446 and is
explained in detail in later sections of this article.
PFKFB3-P•F-6-P Structure
The electron densities of the crystals soaked with F-2,6-P2 show F-2,6-P2 to be
dephosphorylated to F-6-P within the catalytic pocket of the bisphosphatase domain. The
phosphate transferred from O2 of F-2,6-P2 was covalently bound to NE2 of His253 with a
distance of 1.7Å in a covalent phospho-enzyme intermediate state (PFKFB3-P•F-6-P). The
distance between the His-P phosphorous and O2 of F-6-P, the leaving group, is 3.4Å. The
oxygens of the His-P phosphate make numerous interactions with the protein residues such that
the E-P state is stabilized. The residues involved in the interactions with the E-P phosphate are
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Figure 2.3. The minimal enzymatic reaction. The various enzyme states of PFKFB3 through
a minimal enzymatic reaction are shown: free enzyme (E), the Michaelis complex (E•F-2,6-P2),
phospho-enzyme intermediate (E-P•F-6-P), and the states of product release (E-PE•Pi).
Arg252, His387, and Asn259. The details of these interactions are described in following
sections, and they are summarized in Table 2.1. The improved PFKFB3-P•F-6-P model
described here is an extension of resolution and confirms the orientation previously described by
PDB ID:2I1V(Kim, Cavalier et al. 2007). A similar model of PFKFB in the E-P•F-6-P
intermediate state has been previously described using the rat liver isoform (RL2K) of
PFKFB(Lee, Olson et al. 1997). Unfortunately, conclusions regarding the human PFKFB3
should be drawn cautiously from the RL2K model, as this was a truncated form, which lacked
the kinase domain and thirty residues of the C-terminus. As a result, the bound F-6-P was found
near the interface of two protein molecules within the crystal lattice, and the waterbridgeinteractions between the analogous Thr440 and F-6-P, whose importance is described in
later sections, was lost. These circumstances resulted in a notably different position of F-6P(Lee, Olson et al. 1997; Yuen, Mizuguchi et al. 1999).
PFKFB3AlF4 Structure
A crystal soaked with NaF and AlCl3 shows an electron density representing a square
planar AlF4 within the catalytic pocket of the PFKFB3 bisphosphatase domain (Figure 2.4A).
The metal makes two collinear axial bonds to NE2 of His253 and to the oxygen of a water
molecule, each with the distance of 2.1Å and 1.9Å, respectively. As shown in Figure 2.4A, F3
interacts with His387, F4 with Asn259 and Arg252, and F2 with Arg252. F1 of AlF4 makes a
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Table 2.1. Notable interactions between the
bisphosphatase active site ligands and the protein.
Protein Atoms
Arg252 NH1

His253
Asn256
Asn259
Glu322
His387

NE
NE2
ND2
OD1
OE2
ND1

His-P
O1 (3.0)
O3 (3.2)
O3 (2.9)
P (1.7) *
O1 (3.1)
O2 (2.8)

AlF4
F4 (2.8)
F2 (3.2)
F2 (2.7)
Al (2.1)
F1 (3.5)
F4 (3.0)

PPi
O4 (3.0)
O5 (3.3)
O5 (3.0)
P2 (3.5)
O3 (3.0)
O4 (3.0)
O6 (2.6)
F3 (2.6) O (3.3)

F6P

O2 (2.5)

Tyr333
Arg347

OH
O3P (2.6)
NH1
O3P (2.7)
NH2
O1P (2.9)
Tyr362
OH
O1P (2.5)
Arg392 NH1
O2P (2.6)
Values in parentheses are distances given in angstroms.
* Indicates a covalent bond.

unique short-range interaction with Asn256. Geometric details of the interactions are provided
in Table 2.1.
Consequently, the atoms of bound AlF4, together with the apical water and NE2 of
His253 constitute, a tetragonal bipyramidal structure, which seems to mimic a trigonal
bipyramidal phosphorane structure that is transiently formed during the phosphoryl transfer
reaction. The apical water molecule also makes a short-range, 2.8Å, interaction with Glu322.
This finding strongly suggests the function of Glu322 is to neutralize the leaving group and to
activate the attacking water molecule.
The PFKFB3•AlF4 structure is the first PFKFB3 model described in which the product of
the phosphatase domain, F-6-P, is absent. It is also the first structure in which the invariant
region (residues 440-446), whose amino acid sequence and conformation is strongly conserved
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Figure 2.4. Aluminum tetrafluoride within the active site. (A) A stereo view within the
bisphosphatase active site of the PFKFB3•AlF4 model is shown. The mesh represents the |Fo| |Fc| electron density omit map of aluminum tetrafluoride and a bound water molecule within the
bisphosphatase active site. The map is contoured at 3.0levels. Arg252, Asn259, and His387
interact with the peripheral fluorines of aluminum tetrafluoride. Glu322 interacts with a water at
the apex of the bipyramidal structure. The aluminum atom is situated 1.9Å from the water and
2.1Å from His253. The dotted lines mark significant interactions. Molecules/residues of interest
are represented in stick models. (B) Shown is a ribbon representation in stereo view of the
overlapping bisphosphatase active sites of the PFKFB3-P•F-6-P(green) and PFKFB3•AlF4
(yellow) models. C-terminal residues 440-446 of the PFKFB3•AlF4 model can no longer be
tracked. Spheres represent the positions of the C-alphas of the missing residues as projected
from the PFKFB3-P•F-6-P model.
among all four PFKFB isoforms, is disordered (Figure 2.4B). Details regarding this particular
conformational change will be discussed in the following sections.
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PFKFB3•PPi Structure
The crystal soaked with pyrophosphate and F-6-P showed electron density representing
pyrophosphate (PPi) within the bisphosphatase site (Figure 2.5A), while the kinase site was
occupied by two pyrophosphate molecules (data not shown). Within the bisphosphatase domain,
the second phosphorous of the pyrophosphate and its conjugate oxygens have a lower
occupancy. The high occupancy phosphorus atom is 3.5Å from His253. Although it was
included in the soaking solution, F-6-P is absent from the bisphosphatase active site, suggesting
that the E•Pi•F-6-P complex is not favored. This model can be taken as a representative of the
E•Pi state.
Residues 440-446, which were interpreted as a random coil in all models before the
PFKFB3•AlF4 structure, in which it was disordered (Figure 2.5C), can now be seen as a weak,
continuous density which was interpreted as an -helix extending outward from the active site
(Figure 2.5C).
Comparison of Bisphosphatase Active Sites
Three models are described above (PFKFB3-P•F-6-P, PFKFB3•AlF4, and PFKFB3•PPi).
Within each of these three models, a representation of the transferred 2-phosphate (His-P, AlF4,
and PPi, respectively), each at a various stage of the catalytic reaction (E-P•F-6-P, E-P-F-6-P/EP-H2O transition states, and E•Pi, respectively), can be extracted. Within each of these
representations, the represented oxygens of the transferred 2-phosphate maintain interactions
with His387, Asn259, and Arg252 (Table 2.1). Therefore, these residue side-chains must remain
in contact with the 2-phosphate oxygens throughout the reaction.
Glu322 makes interactions with the O2 of F-6-P in the PFKFB3-P•F-6-P model, with the
apical water of the bipyramid within the PFKFB3•AlF4 model, and with the O1 of high
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Figure 2.5. Pyrophosphate within the active site. (A) A stereo view within the
bisphosphatase active site of the PFKFB3•PPi model is shown. The mesh represents the |Fo| -|Fc|
electron density omit map of PPi within the bisphosphatase active site. The map is contoured at
3.0levels. Arg252, Asn259, and His387 interact with the pyrophosphate oxygens that are
assumed to be at the positions of the 2-phosphate oxygens of F-2,6-P2. The phosphorous is
situated 3.5Å from His235. The dotted lines mark significant interactions. Molecules/residues
of interest are represented in stick models. (B) Ribbon representations in stereo of the
overlapping models of PFKFB3-P•F-6-P (green) and PFKFB3•PPi (magenta) are shown.
Molecules/residues of interest are represented in stick models. Upon the absence of F-6-P, two
waters which bridge interactions with the C-terminal segment covering the active site are lost.
The C-terminal residues 440-446 are no longer seen as a random coil extending over the
bisphosphatase active site, but as a helix extending outwards away from the active site. After
the loss of the two water bridged interactions, Thr440 rotates out of the active site.
Simultaneously, His441 replaces Arg442 in a -cation interaction with Tyr333. Arg442 can then
commence the coiling of the observed helix. (C) Shown are the C-terminal residues of the
PFKFB3•PPi model. Residues 425-436 are represented as a ribbon while residues 437-446 are
represented with sticks. The mesh represents the |Fo| -|Fc| electron density omit map of Cterminal residues 437-446 of the bisphosphatase active site. The map is contoured at 2.0levels.
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occupancy phosphate of PPi within the PFKFB3•PPi model (Table 2.1). The significance of this
will be explained in later sections.
The O1 oxygen of the high occupancy phosphate of PPi within the PFKFB3•PPi model is
at the approximately same position as the O2 of F-6-P within the PFKFB3-P•F-6-P model. The
summation of the atoms within these two molecules yields a representation of the bisphosphatase
substrate F-2,6-P2 (Figure 2.6A), allowing a hypothetical model of the Michaelis complex
(Figure 2.6B).
Because of the absence of F-6-P within the PFKFB3•PPi model, two waters, which
bridge extensive interactions between F-6-P and the C-terminus in the PFKFB3-P•F-6-P model,
are lost. The C of Thr440 moves 2.5Å out of the active site, and the side-chain rotates 113-132°
outward from the active site. Simultaneously, His441 acts to replace Arg442 in a -Cation
interaction with Tyr333. The displacement of Arg442 allows coiling of the newly observed helix (Figure 2.5B).
Degradation of Fructose-2,6-Bisphosphate
Based on the three structures, a molecular model of the F-2,6-P2ase reaction of the human
inducible form of PFKFB is suggested. This mechanism is in direct agreement with the
mechanism suggested for the human testes form of PFKFB(Yuen, Mizuguchi et al. 1999). The
models introduced in this work, in particular PFKFB3AlF4, increase confidence in assumptions
concerning the mechanism of PFKFB3 by offering structural details that were not previously
available in any isoform.
Binding of Substrate (E  E•F-2,6-P2). In Figure 2.6B, the F-2,6-P2 representation
summed from the high occupancy phosphate of the PFKFB3•PPi model and the F-6-P of the
PFKFB3-P•F-6-P model confirms that the 6-phosphate moiety is recognized by Arg347, Lys351,
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Figure 2.6. A hypothetical representation of the Michaelis complex (E•F-2,6-P2). Here is
the Michaelis complex as constructed using ligands from the PFKFB3-P•F-6-P and
PFKFB3•PPi models. Molecules/residues of interest are represented in stick models. (A) A
stereo view of the overlapping bisphosphatase active sites of both the PFKFB3-P•F-6-P(green)
and PFKFB3•PPi(magenta) models is shown. The pyrophosphate of the PFKFB3•PPi model
and the F-6-P of the PFKFB3-P•F-6-P model have been included but not the covalently bound
phosphate. The lower occupancy phosphoryl group of PPi has been grayed. The remaining
ligand atoms can be used to construct a continuous representation of bound F-2,6-P2. (B) A
complete representation of the Michaelis complex projection is shown in pink. The 2-phosphate
moiety is recognized by residues Arg252, Asn259, and His387. The 6-phosphate moiety is
recognized by residues Arg347, Lys351, and Tyr362. (C) The ligands from all three models are
displayed. The lower occupancy phosphoryl group of PPi has been grayed. The direct inversion
of oxygen stereochemistry, through the E•F-2,6-P2 to E-P states with the transition state
represented by the equatorial plane formed by the peripheral fluorines of AlF4, can be tracked.
By tracking through all three representations of the 2-phosphate phosphorous (His-P, AlF4, PPi),
one would create an approximately straight line punctuated at the ends by the NE2 of His253 and
the O2 of F-6-P.
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and Tyr362 and that the 2-phosphate moiety is recognized by residues His387, Asn259, and
Arg252. The C-terminal residues 440-446 are stabilized as a random coil through watermediated interactions with F-2,6-P2.
Formation of the Phospho-Enzyme Intermediate (E•F-2,6-P2  E-P•F-6-P). In Figure
2.6C, the three newly introduced models allow us to observe three positions of the 2-phosphate
during the phosphoryl transfer; PPi, AlF4, and His-P. By tracking through all three
representations of the phosphorous of 2-phosphate (His-P, AlF4, PPi), a nearly straight line
punctuated at the ends by the NE2 of His253 and the O2 of F-6-P can be seen, suggesting an “inline” transfer mechanism(Kountz, Freeman et al. 1988). This supports the direct inversion of
oxygen stereochemistry through the PFKFB3-P•F-6-P to PFKFB3•PPi models with the transition
state represented by the equatorial plane formed by the peripheral fluorines of AlF4. An
equatorial plane created by the migrating peripheral oxygens of phosphate was hypothesized
(Yuen, Mizuguchi et al. 1999), but never before has it been so clearly depicted. Note that the
arrangement of AlF4, bound by PFKFB3, cannot exactly mimic the trigonal bipyramidal
transition state of the phosphoryl-transfer reaction but is considered an adequate approximation
in phosphoryl-transfer mechanisms(Coleman, Berghuis et al. 1994; Fisher, Smith et al. 1995;
Rittinger, Walker et al. 1997; Olesen, Sorensen et al. 2004; Golicnik 2010).
Upon binding of F-2,6-P2, the NE2 of His253 is in position for a nucleophilic attack on the 2phosphate. This attack is aided by the interactions of 2-phosphate with Arg252, His387, and
Asn259. The resulting interactions would stabilize the transition state by delocalizing the
electrons in the 2-phosphate towards the side-chains of residues Arg252, His387, and Asn259
making the phosphorous of the 2-phosphate more electrophilic. This would enhance the
nucleophilic attack of the lone pair of electrons of the NE2 of His253. The removal of 2-
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phosphate from F-2,6-P2 would leave a highly basic anion that would need to be neutralized to
prevent reformation of the reaction substrates. The general proximity of Glu322 suggests that it
is positioned to function as the general acid and donates a proton to the leaving O2 after His-P
formation. This is consistent with kinetic studies of the conserved Glu327 within the rat liver
isoform, which suggests that Glu327 acts as both a general acid during the E-P formation and a
general base during E-P breakdown(Kountz, Freeman et al. 1988; Sakurai, Hasemann et al.
2000). The reaction mechanism resulting in the E-P•F-6-P intermediate is summarized in Figure
2.7.
Release of F-6-P and Degradation of the Phospho-Histidine Intermediate (E-P•F-6-P 
E-P  E•Pi). Upon the departure of the F-6-P and the two waters which bridge interactions
between F-6-P and residues 440-446, this segment of the C-terminus is no longer stabilized as a
random coil. A molecule of water would then move in to the apex of a tetragonal bipyramidal
configuration and the mechanism by which E-P would breakdown is presumably the reverse of
its formation. Glu322 would withdraw a hydrogen from the water and the resulting strong anion
would attack the electrophilic phosphate while the transition state is stabilized by residues
Arg252, His387, and Asn259 (Figure 2.7). The importance of the water found at the apex of the
bipyramid now becomes immediately apparent. The activation of water by Glu322 has been
hypothesized (Kountz, Freeman et al. 1988; Yuen, Mizuguchi et al. 1999; Sakurai, Hasemann et
al. 2000), but the placement of a water molecule in a position of attack has never before been
depicted. The track of the peripheral oxygens through the equatorial transition state during the
formation of free phosphate is also represented by the PFKFB3•AlF4 model. In actuality,
because of the absence of F-6-P in the PFKFB3•AlF4 model, the track of the peripheral oxygens
during the phospho-histidine breakdown is more directly portrayed than the formation of the
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Figure 2.7. The complete mechanism of phospho-histidine formation/degradation. This
schematic was prepared with ChemBioDraw (ChemBioDraw Ultra 10.0 CambridgeSoft, 100
CambridgePark Drive, Cambridge, MA 02140). Brackets indicate a transition state in which a
direct inversion of phosphate stereochemistry occurs. Upon binding of F-2,6-P2, His253 is in
position for a nucleophilic attack on the 2-phosphate. Interactions with Arg252, His387, and
Asn259 stabilize the transition state by delocalizing the electrons towards the residues making
the P of 2-phosphate more electrophilic. This enhances the nucleophilic attack of the lone pair of
electrons of the NE2 of His253. Glu322 acts as a general acid and donates a proton to neutralize
the highly basic anion on the first product. Glu322 would then withdraw a hydrogen from a
water, and this strong anion would attack the electrophilic phosphate while the transition state is
stabilized by residues Arg-252, His-387, and Asn-259 creating the second product

phospho-histidine.

Upon the formation of the free phosphate, residues 440-446 shift away from

the active site and appear to coil into an -helix.
Discussion
The three models introduced in this article provide a clearer understanding of the
bisphosphatase reaction of the inducible form of the bifunctional enzyme by both supporting
previous assumptions derived from other isoforms, and distinguishing unique characteristics of
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this particular polypeptide. The PFKFB3-P•F-6-P model allows confirmation of the positioning
of the fructose and 6-phosphate atoms as well as the residues responsible for their binding,
whereas the PFKFB3•PPi does the same for the atoms of the 2-phosphate. The PFKFB3•AlF4
model directly illustrates the stereochemistry of the bisphosphatase reaction for the first time
amongst all isoforms.
It has been suggested that the reduced bisphosphatase activity of PFKFB3 is solely due to
the presence of a serine at residue 302 instead of an arginine as conserved in the other isoforms
(Figure 2.2). This residue is said to interact with the 2-phosphate and further stabilizes the
transitions state, if conserved(Hasemann, Istvan et al. 1996; Lee, Li et al. 2003; Kim, Manes et
al. 2006). Studies have reported that the restoration of this serine to arginine rescues the ability
to generate and degrade the His-P intermediate(Manes and El-Maghrabi 2005). Strangely,
however, despite not a having arginine at position 302, PFKFB3 has the ability to form the
phospho-histidine intermediate but merely lacks the ability to degrade
it. This article provides structural evidence of a conformational change in C-terminal residues
440-446 and suggests that the reason for the depressed bisphosphatase activity may be more
complex than simply a single mutated residue. The absence of F-6-P from the active site causes
rearrangement of the C-terminus residues 440-446. Perhaps, this is suggestive that
bisphosphatase activity is further regulated through the control of ligand binding and product
release, or perhaps the degradation of the active site after the release of F-6-P.
It should be noted that the pivotal residues of this conformational change (Thr440,
His441, Arg442) are absolutely conserved across all known mammalian isoforms of fructose2,6-bisphosphatase. In addition, previous works with the rat liver isoform, which was truncated
just before the Thr-His-Arg segment, resulted in a nine-fold increase in kcat, an eleven-fold
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increase in Km, and relief of pH dependent regulation of bisphosphatase activity(Lin, Kurland et
al. 1994).
No similar conformation change in residues 440-446 has been seen in any other isoforms
(Figure 2.1B), yet additional studies are needed to conclusively ensure that this phenomenon is
unquestionably unique to PFKFB3. However, from our research, we are confident that the cation interaction between Arg442 and Tyr333 is unique to PFKFB3 among all currently known
isoforms. In both PFKFB1 and PFKFB4 models, this conserved arginine forms a salt bridge
with an aspartic acid, namely Asp353 and Asp351, respectively. Arg442 does not interact with a
glutamic acid, Glu348, at this same position within PFKFB3(Figure 2.2).
Materials and Methods
Preparation and crystallization of PFKFB3
Protein preparation and crystallization was similar to methods previously described(Kim,
Manes et al. 2006; Kim, Cavalier et al. 2007). The His6-tagged human inducible isoform of the
bifunctional enzyme, PFKFB3, was expressed in Escherichia coli BL21 (DE3) pLysS and was
purified by Ni-NTA affinity columns. The protein sample was further purified using Qsepharose anion-exchange chromatography. This purified protein was kept at a concentration of
8 mg ml-1 in pH 8.0, 20 mM Tris-HCl, 10 mM NaxPi, 5 mM -mercaptoethanol, and 5%
glycerol. Crystal were grown using sitting drop vapor diffusion with a 1:1 (v/v) mixture of
protein with a mother liquor of 100 mM Tris-HCl, pH 7.5, 20-25% ethylene glycol, 200-400mM
Tartaric Acid, 5% glycerol, and 12% polyethylene glycol 4000. Crystals in a size of 0.2 X 0.2 X
0.05 mm were grown in two to three weeks.
The crystals were soaked with cryoprotectant solutions for 0.5 to 2 hours to allow binding
of the desired ligands. Cryoprotectant solutions consisted of 20 mM Tris-HCl pH 7.5 buffer and
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12% polyethylene glycol 4000, and were enriched with 35% ethylene glycol and the targeted
ligands. The PFKFB3-P•F-6-P crystal was soaked with 3mM ADP 0.5mM F-2,6-P2. The
PFKFB3•AlF4 crystal was soaked with 3mM ADP, 0.5mM F-6-P, 2mM AlCl3, and 8mM NaF.
The PFKFB3•PPi crystal was soaked with 3mM PPi. The soaked crystals were flash cooled at
100K and the temperature was maintained during data collection using an Oxford cryo device.
Data Collection and Processing
Diffraction data for the PFKFB3•AlF4 and the PFKFB3-P•F-6-P crystals was collected at
The Gulf Coast Consortium Protein Crystallography Beamline (PX1) in The Center for
Advanced Microstructures and Devices (CAMD), Louisiana State University, Baton Rouge, LA
using a x-ray source wavelength of 1.3808Å the data was recorded on a Mar 165mm CCD
detector and was integrated, merged, and scaled using HKL2000(Otwinowski and Minor 1997).
Diffraction data for the PFKFB3•PPi crystal was collected at The Northeastern
Collaborative Access Team (NE-CAT) beamline at the Advanced Photon Source (Argonne
National Laboratory) using an x-ray source wavelength of 0.9792Å. The data was recorded on
an ADSC Q315 (315mm X 315mm) detector and was integrated, merged, and scaled using
HKL2000(Otwinowski and Minor 1997). Statistics of the diffraction data and structure
refinement are summarized in Table 2.2. All crystals belonged to the P6522 space group, and the
cell dimensions were similar.
Structure Determination and Refinement
The reduced data was formatted for the program suite of CCP4(Bailey 1994; Potterton,
Briggs et al. 2003)and 5% of the data was marked for free R-factor measurements in subsequent
structure refinements. Initial models of all complexes were determined using REFMAC(Vagin,
Steiner et al. 2004) within the CCP4 suite with the PFKFB3•ADP•EDTA complex (PDB ID:
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Table 2.2. Statistics of reflection data and structure refinements (PFKFB3).
Liganding
PFKFB3•AlF4
PFKFB3-P•F-6-P
PFKFB3•PPi
Space group
P6522
P6522
P6522
Unit cell dimension (Å)
102.71 X 102.71 X 257.04 102.15 X 102.15 X 259.44 102.98 X 102.98 X 258.13
Wilson Plot B Value (Å2)
45.7
55.6
41.2
Resolution range (Å)
30.0 - 2.25
30.0 - 2.45
35-2.30
Reflections Observed
351,069
434,030
927,757
Unique Reflections
38,530
30,381
36,888
Reflections Rfree set
1,951
5,839
1,975
Completeness (%)
99.5 (98.5)
99.6 (98.7)
100 (99.9)
Redundancy
4.7 (4.6)
5.8 (5.7)
7.6 (7.8)
18.5 (1.8)
14.9 (1.4)
20.0(2.7)
<I/
Rsym
0.071 (0.462)
0.092 (0.824)
.078 (0.756)
Rcrys
0.200
0.193
0.184
Rfree
0.242
0.247
0.236
No. of amino acids
431
441
439
No. of protein atoms
3,534
3,607
3,584
No. of hetero atoms
43
67
55
No. of waters
260
175
320
R.M.S.D. bond lengths (Å)
0.022
0.024
0.024
Angles (°)
1.8
2.2
2.1
Mean B factor
Protein atoms (Å2)
43.8
42.5
31.2
Hetero atoms (Å2)
51.1
36.5
39.7
2
Water atoms (Å )
53.2
48.0
40.4
Ramachandran Outliers(%) 0.0
0.2
0.5
Ramachandran Favored(%) 96.3
93.8
97.2
Poor Rotamers (%)
5.4
8.5
5.3
Rsym = Σ h(Σ j|Ihj - <Ih>|/ Σ Ih,j), where h=set of Miller indices, j=set of observations of reflection h, and <Ih>=the mean
intensity. R.M.S.D. values are deviation from ideal values. Rcrys= Σh||Fo,h| – |Fc,h||/ Σh|Fo,h|. Rfree was calculated using 5% of
the complete data set excluded from refinement. The numbers in parentheses represent values from the highest resolution
shell (2.33-2.25 Å for E•AlF4 complex, 2.54-2.45 Å for the E-P•F-6-P complex, and 2.34-2.30 Å for the E•PPi complex).
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2AXN(Kim, Manes et al. 2006)) as the starting molecule after removal of the ligand and solvent
molecules.

The initial model went through many cycles of manual model rebuilding and

validation using the program COOT(Emsley and Cowtan 2004). Binding of the ligands was
confirmed, referring to the |Fo| -|Fc| omit maps that were generated, when Rcrys/Rfree reached
0.25/0.28 or below and the ligands were incorporated into the complex models.
As summarized in Table 2.2, the PFKFB3-P•F-6-P complex has Rfree/Rcrys of 0.247/0.193
using a total of 3,849 scatterers, including solvent molecules, against all 30,381 available
reflections in the resolution range of 30.0–2.45Å. The structure contains a total of 441 amino
acid residues of the full-length protein of 520 residues. As in the PFKFB3•ADP•EDTA complex,
the C-terminus (residues 446–520) is mostly disordered.
The final structure of the PFKFB3•AlF4 complex has Rfree/Rcrys of 0.242/0.200 using a
total of 3,837 scatterers, including solvent molecules, against all 38,530 available reflections in
the resolution range of 30.0–2.25Å. The structure contains a total of 431 amino acid residues of
the full length protein of 520 residues.
The final structure of the PFKFB3•PPi complex has Rfree/Rcrys of 0.236/0.184 using a total
of 3,959 scatterers, including solvent molecules, against all 36,888 available reflections in the
resolution range of 35.0–2.30Å. The structure contains a total of 439 amino acid residues of the
full-length protein, which consists of 520 residues.
The atomic coordinates and structure factors of the PFKFB3-P•F-6-P complex (PDB ID:
3QPV), the PFKFB3•AlF4 complex (PDB ID: 3QPW), and the PFKFB3•PPi complex (PDB ID:
3QPU) have been deposited in the RCSB Protein Data Bank.
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CHAPTER 3: REVIEW OF LITERATURE, VLDE
Diversification of Natural Products
Natural Products Offer Unique Scaffolding
Natural products continue to play a large role in the drug discovery and development
processes. According to a survey of clinically available therapeutic agents, a very large
percentage of drugs are in fact natural products or at least have clearly discernible connection to
natural products (Danishefsky 2010; Newman and Cragg 2012). Although the prevalence of
natural compounds as drugs is not entirely understood, certain advantages of natural occurring
materials can be inferred. Firstly, natural products are biosynthesized by their hosts to interact
with proteins, such as enzymes or receptors. These types of biomolecules are generally the
targets of therapeutic agents. Additionally, natural products by definition are housed in a living
host. Drug candidates often fail due to the incompatibility with biological hosts, thus the crude
biocompatibility of natural products can be quite desirable (Danishefsky 2010). It should also be
noted that the design of potential therapeutics by chemical synthesis is usually weighted by
“drug-likeness”. This tends to lead researchers in a direction that is non-analogous to the
composition of natural products since the chemical compositions of natural drugs are often
counter-intuitive. Correspondingly, Lipinski's “Rules of Five” often do not apply to natural
products when considering “druggable chemical entities” (Lipinski 2004; Keller, Pichota et al.
2006; Macarron 2006). Therefore, natural products often offer a complex and non-intuitive
scaffolding ideal for drug development.
Unfortunately, biologically active natural products often possess a valuable, though not
necessarily optimized, pharmacophoric space (Danishefsky 2010). Also, some natural product
substructures are effectively inaccessible to chemical modification and the total chemical

46

synthesis of a natural product can be a daunting task. Thusly, perturbations to the chemical
structure of natural products through other means must be investigated. Investigations into the
biosynthetic pathways of these natural products may provide the necessary opportunities to
produce novel analogs of natural products via biosynthetic approaches. Already, studies of the
biosynthetic pathways of natural products have led to the diversification of the antibacterial
erythromycin, the anthelmintic avermectins, and the antitumor indolocarbazoles (Figure 3.1).
The diversifications of these scaffolds were achieved through the genetic manipulation of
biosynthetic gene clusters along with the use of alternative biosynthetic precursors, and
recombinant proteins for chemoenzymatic synthesis (McDaniel, Thamchaipenet et al. 1999;
Cropp, Wilson et al. 2000; Sanchez, Mendez et al. 2006; Mahmud, Flatt et al. 2007). These
studies provide examples of how the understanding of a biochemical pathway can lead to the
diversification of a group of biologically important compounds.
Diversification of the Erythromycin Scaffold by Genetic Manipulation
The polyketide erythromycin and its semisynthetic derivatives are the third most widely
used class of antibiotics in the world (Figure 3.1) (McDaniel, Thamchaipenet et al. 1999).
Erythromycin has been in clinical use for over 50 years and was first isolated by McGuire et al.
in 1952 (Mcguire, Bunch et al. 1952; Pal 2006). The specific antibacterial action of
erythromycin is attributed to its ability to obstruct protein synthesis by inhibiting ribosomal
activity (Vester and Douthwaite 2001). Due to the complexity of its chemical structure, the total
chemical synthesis of this important antibiotic by R. B. Woodward and his colleagues took more
than a decade to elucidate (Woodward, Logusch et al. 1981; Pal 2006). R. B. Woodward was
followed by a series of medicinal chemists who prepared analogs leading to a second generation
of macrolide antibiotics such as clarithromycin, azithromycin, and others (Chu 1995).

47

Figure 3.1. Differentiated Scaffolds. Shown are the chemical structures of natural products
whose scaffolds have been differentiated by methods resulting from the study of biosynthetic
pathways.
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Eventually, these efforts exhausted the chemical modifications available at the existing
functional groups of the macrolide ring, but most of the ring was effectively inaccessible to
chemical modification (McDaniel, Thamchaipenet et al. 1999). Upon the discovery of the
programmed nature of modular polyketide biosynthesis (Cortes, Haydock et al. 1990; Donadio,
Staver et al. 1991), diversification of polyketides could then be accomplished using genetic
engineering strategies (Mcdaniel, Ebertkhosla et al. 1995; Katz 1997).
The modular polyketide synthases are encoded by a cluster of contiguous genes and are
an organization of catalytic domains that both bind and modify the polyketide backbone. Each
module consists of a ketosynthase, an acyltransferase and an acyl carrier protein (O'Hagan 1991;
McDaniel, Thamchaipenet et al. 1999). The acyl carrier protein catalyzes the extension of the
growing polypeptide chain while the choice of 2-carbon extender in the form of a CoA activated
small organic acid thioester is selected by the specificity of an acyltransferase (Oliynyk, Brown
et al. 1996; Liu, Thamchaipenet et al. 1997; Ruan, Pereda et al. 1997). The final state of each 2carbon extender is determined by the additional presence of varying catalytic domains in the
module such as ketoreductases, dehydratases, and enoyl reductases. In summary, the
composition of each module encodes the structure of each 2-carbon unit while the order of
modules forms a template for the polyketide product (McDaniel, Thamchaipenet et al. 1999).
The discovery that the structural diversity of polyketides is governed by a sequence of
catalytic modules made it feasible to contemplate modifications to the chemically intractable
sites of such molecules by genetic engineering. Using such techniques, McDaniel,
Thamchaipenet et al. created a library of structurally diverse polyketides. Using the polyketide
synthase responsible for the production of the macrolide ring of erythromycin as a starting point,
combinatorial biosynthetic strategies were utilized to incorporate components from different
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polyketide pathways. The diversity of the generated library would be prohibitively impractical
to attempt by means of chemical synthesis (McDaniel, Thamchaipenet et al. 1999).
Diversification of the Avermectin Scaffold by Alternative Precursors
The avermectins are a group of anthelmintic macrolides produced by Streptomyces
avermitilis (Figure 3.1) (Campbell and Benz 1984). Like other polyketides, the avermectins are
synthesized by a modular polyketide synthase using decarboxylative condensations to grow a
polyketide chain from a starter unit with catalysis, extender unit selection, and extender
stereochemistry governed by the catalytic domains comprising each module (Katz 1997).
Previous studies aimed at diversification of the polyketide scaffold, such as that of erythromycin
(McDaniel, Thamchaipenet et al. 1999), focused primarily on combinations of different
polyketide synthase components to produce perturbations in extender chemical structure (Stassi,
Kakavas et al. 1998; McDaniel, Thamchaipenet et al. 1999). Dutton, Gibson, et al. extended the
structural diversity of polyketide scaffolds through the incorporation of different polyketide
biosynthetic starter units (Dutton, Gibson et al. 1991).
The extension of the avermectin backbone initiates from a starter unit comprised of either
S(+)--methylbutyryl-CoA or isobutyryl-CoA. One step in the formation of the acyl-CoA form
of the -branched-chain fatty acid starter units is a branched-chain -keto acid dehydrogenase
reaction (Dutton, Gibson et al. 1991; Denoya, Fedechko et al. 1995). A S. avermitilis mutant,
which lacks a functional branched-chain -keto acid dehydrogenase, was isolated (Hafner,
Holley et al. 1991). This mutant could only synthesize natural avermectins when the branched-chain fatty acids were added to the fermentation medium. However, the addition of
alternative fatty acids resulted in the formation of a series of novel avermectins (Dutton, Gibson
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et al. 1991). The efforts necessary to reproduce this series of avermectins through chemical
synthesis would be staggering.
Diversification of the Antitumor Indolocarbazoles by Recombinant Enzymes
The indolocarbazoles are an important class of natural products isolated from
actinomycetes, cyanobacteria, slime molds, and marine invertebrates (Gribble 1993; Knolker and
Reddy 2002). The indolocarbazoles exhibit antitumor and neuroprotective activities through the
inhibition of protein kinases and DNA topoisomerases, and through direct DNA intercalation
(Akinaga, Sugiyama et al. 2000; Fischer, Rodriguez et al. 2002; Prudhomme 2003). The
indolocarbazoles rebeccamycin and staurosporine are derivatives of the indolo[2,3-a]pyrrolo[3,4c]carbazole ring system to which a sugar residue is attached (Figure 3.1). These indolocarbazoles
differ in the attachment of the carbohydrate and in the composition of the pyrrole moiety, and
these differences are essential for target selectivity (Sanchez, Mendez et al. 2006). Upon the
discovery of the rebeccamycin (reb) and staurosporine (sta) biosynthetic gene clusters (Onaka,
Taniguchi et al. 2002; Onaka, Taniguchi et al. 2003; Sanchez, Mendez et al. 2006), the stage was
set to elucidate the steps in the biosynthesis of indolocarbazoles and for the generation of novel
indolocarbazole analogs by genetic engineering.
Sanchez, Mendez et al. dissected and reconstituted the entire biosynthetic pathway for
rebeccamycin in a Staphylococcus epidermidis host (Sanchez, Zhu et al. 2005). By rationally
expressing different combinations of reb genes, numerous rebeccamycin derivatives were
produced within the genetically engineered host. Later, sta genes responsible for the
differentiation of the indolocarbazole’s carbohydrate components were also introduced.
Selective expression of sta genes lead to further derivatization of the indolocarbazole scaffold
including alternative glycosylation by a number of deoxysugars (Sanchez, Mendez et al. 2006).
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Because of the potential therapeutic applications of indolocarbazole family of natural products,
the demonstrated ability to synthesize indolocarbazole derivatives through biological processes
within a convenient bacterial host can prove to be an invaluable tool.
The Aminocyclitol Class of Natural Products
The Variety of Aminocyclitols
Another family of natural products whose biosynthesis is being studied in hopes that such
knowledge could lead to the development of clinically important compounds is the
aminocyclitols. The aminocyclitols are a class of microbially generated natural products with
many clinical and agricultural applications (Mahmud 2003; Davies 2006). Included amongst the
aminocyclitols are the aminoglycoside antibiotics, the C7N-aminocyclitols, and the fivemembered ring aminocyclitols or cyclopentitols. The aminoglycoside antibiotics were among
the first clinical antibiotics and remain an important group of drugs for the treatment of
infections (Prasad, Verma et al. 2006; Yamamura, Kawada et al. 2008). The aminoglycoside
antibiotics work through the inhibition of the bacterial ribosome and thusly the disruption of
protein synthesis. The C7N-aminocyclitol and the cyclopentitol groups of natural products are
structurally more diverse and display a variety of biological activities. Amongst the C7Naminocyclitol family is the antifungal, antibiotic validamycin A. The aminocyclitols are derived
biosynthetically from simple sugar units which are in most cases formed by a family of enzymes
known as sugar phosphate cyclases (SPCs) (Llewellyn and Spencer 2006; Mahmud, Flatt et al.
2007; Wu, Flatt et al. 2007). The aminoglycoside antibiotic precursors are produced by the 1myo-inositol 1-phosphate synthase and the 2-deoxy-scyllo-inosose synthases while the 2-epi-5epi-valiolone synthases are involved in the biosynthesis of the C7N-aminocyclitol natural
products. Uniquely, the five-membered ring aminocyclitols may be derived from aminosugars
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via a yet to be determined mechanism (Sakuda, Sugiyama et al. 2001; Sugiyama, Nagasawa et al.
2002; Kudo, Kasama et al. 2007). Because of the biological roles of the aminocyclitols, the
biosynthetic pathways of these natural products are under investigation with the hope that this
knowledge could lead to the development of clinically significant therapeutics.
The Aminoglycosides
The aminoglycosides were the first important therapeutic agents produced by bacterial
fermentation and all work through essentially the same mode of antibacterial action. They
prevent the translation of proteins by binding the 30S subunit of the 70S prokaryotic ribosome
and interfere specifically with transfer RNA interactions with messenger RNA in the decoding
site of the ribosome (Davies 2006). Despite the similar antibacterial action, new studies using
high resolution NMR analyses and X-ray crystallographic structures clearly describe differences
in binding of the various classes of aminoglycosides and distinct modes of action (Lynch,
Gonzalez et al. 2003; Ogle and Ramakrishnan 2005). Examples amongst the aminocyclitol
containing aminoglycosides are the antibiotics streptomycin, hygromycin, butirosin, neomycin,
gentamycin (Figure 3.2).
Streptomycin was first isolated in 1943 by the group of S. A. Waksman and is historically
the second great antibiotic after penicillin. Streptomycin was isolated from actinomycetes, the
focus of Waksman’s career, and it was proven to be particularly effective in the treatment of
tuberculosis, whereas penicillin is ineffective. It was his discovery of streptomycin that was the
primary factor in the awarding of his Noble prize in medicine in 1952 (Kingston 2004). The
precursor of streptomycin is myo-inositol, an ubiquitous compound playing a role in many
cellular and physiological processes in living organisms. Myo-inositol is derivatized from
glucose 6-phosphate in a process involving the enzyme 1-myo-inositol 1-phosphate synthase.
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Figure 3.2. The aminoglycosides. Shown are the chemical structures of various antibiotics
belonging to the aminoglycoside class of natural products
54

Myo-inositol is then tailored by a series of reactions to a more complex aminocyclitol (Mahmud
2009). In streptomycin biosynthesis, myo-inositol is oxidized to scyllo-inosose by myo-inositol
dehydrogenase (StrI) and then transaminated to scyllo-inosamine by scyllo-inosose
aminotransferase (StsC) to produce the aminocyclitol core of streptomycin (Mahmud, Flatt et al.
2007).
Hygromycin is another example of an aminoglycoside antibiotic which uses myo-inositol
as a biosynthetic precursor (Mahmud 2009). Hygromycin was first isolated from Streptomyces
hygroscopicus in 1953, and was first described to have a relatively broad spectrum of modest
activity against gram-negative and gram-positive bacteria (Mann, Gale et al. 1953; Pittenger,
Wolfe et al. 1953). It has recently received a renewed interest due to its effectiveness in the
treatment of swine dysentery by the anaerobic spirochete Serpulina hyodysenteriae (Omura,
Nakagawa et al. 1987). The tailoring of the aminocyclitol unit of this antibiotic involves the
oxidation of C-5 of myo-inositol to give myo-inosose-5, catalyzed by a putative myo-inositol
dehydrogenase, Hyg17, followed by the conversion to 2-L-2-amino-2-deoxyneo-inositol by the
PLP-dependent aminotransferase, Hyg8 (Habib, Scarsdale et al. 2003).
The precursory core of several aminoglycoside antibiotics such as butirosin, neomycin
and gentamycin are formed by the 2-deoxy-scyllo-inosose (DOI) synthases, which catalyze the
conversion of glucose 6-phosphate to DOI (Nango, Kumasaka et al. 2008; Mahmud 2009).
Furthermore, despite being synthesized by different genera of bacteria, these aminoglycosides
also share the amino-pseudo-disaccharide paromamine as a common intermediate. The
significant conservation of biosynthetic gene clusters required for paromamine biosynthesis
facilitated the initial prediction of their biosynthetic pathways. In the synthesis of the
paromamine intermediate, DOI is converted to 2-deoxy-scyllo-inosamine by a PLP-dependent
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aminotransferase. Interestingly, this PLP-dependent aminotransferase is also responsible for the
conversion of 2-deoxy-3-keto-scyllo-inosamine to 2-deoxystreptamine. A dehydrogenase
oxidizes 2-deoxy-scyllo-inosamine to 2-deoxy-3-keto-scylloinosamine. Nacetylglucosaminyltransferase catalyzes the conversion of 2-deoxystreptamine to 2´-Nacetylparomamine. Finally, the paromamine core is completed by 2´-N-acetylparomamine
deacetylase. Considering the number of homologous enzymes, the structural diversity of this
particular set of aminoglycosides is remarkable. Glycosyltransferases further contribute to the
diversity by mediating the attachment of various sugar moieties (Mahmud 2009).
The Five-Membered Ring Aminocyclitols
The five-membered ring aminocyclitols or aminocyclopentitols such as pactamycin,
trehazolin, and allosamidin are of particular interest due to their ability to inhibit glycosidases
and other carbohydrate recognizing enzymes by mimicking the corresponding substrates (Figure
3.3) (Winchester and Fleet 1992). Until recently, the only information available about the
biosynthesis of aminocyclopentitols was derived from conventional feeding experiments with
isotopically labeled precursors which identified glucose as the source of the aminocyclitol
component (Weller and Rinehart 1978; Rinehart, Weller et al. 1980). Recently, the biosynthetic
gene cluster of pactamycin was identified and analyses of the biosynthetic pathway of this
aminocyclopentitol are underway (Kudo, Kasama et al. 2007; Ito, Roongsawang et al. 2009). It
has been proposed that this unique aminocyclitol core is formed by a radical-mediated
rearrangement of a glucosaminyl moiety by a Fe-S radical SAM oxidoreductase (Kudo, Kasama
et al. 2007; Ito, Roongsawang et al. 2009).
The antibacterial pactamycin was isolated in 1962 from the soil bacterium Streptomyces
pactum by scientists at the former Upjohn Company (Bhuyan 1962). This inhibitor of the 30S
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Figure 3.3. The aminocyclopentitols. Shown are the chemical structures of various antibiotics
belonging to the aminocyclopentitol class of natural products

bacterial ribosome unit also showed strong anti-tumor activity but is too toxic for clinical use
(Bhuyan 1962; Hanessian, Vakiti et al. 2011). Pactamycin is comprised of a five-membered ring
aminocyclitol unit linked to 6-methylsalicylic acid, 3-aminoacetophenone, and a 1,1dimethylurea (Wiley, Jahnke et al. 1970; Rinehart, Weller et al. 1980). Hanessian, Vakiti et al.
described pactamycin as the most densely functionalized naturally occurring aminocyclopentitol
known (Hanessian, Vakiti et al. 2011).
In 1986, allosamidin was identified as an inhibitor of chitinase, an enzyme required for
the proper degradation of chitin in insect cuticle. Such an agent capable of preventing the
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degradation of old exoskeleton was sought as a potentially new biological insecticide. Isolated
from the mycelial extract of Streptomyces sp. No. 1713, allosamidin is a pseudotrisaccharide
constructed of two -linked N-acetyl-2-amino-2-deoxy-D-allopyranoside units with an
aminocyclopentitol moiety attached at the reducing end (Sakuda, Isogai et al. 1986; Sakuda,
Sugiyama et al. 2001).
A 1991 screen for trehalase inhibitors uncovered a pseudodisaccharide termed trehazolin.
Trehazolin was isolated from a culture broth of Micromonospora sp. SANK 62390 and consists
of an -glucose monomer linked to the aminocyclopentitol trehazolin via an isourea
functionality. Trehazolin is a particularly potent trehalase inhibitor (Ando, Satake et al. 1991;
Masson, Philouze et al. 2005).
The C7N Aminocyclitols
The C7N aminocyclitols are a class of microbially-derived secondary metabolites,
particularly from soil bacteria of the order of Actinomycetes (Mahmud 2003). Their biological
activities are known to be brought about by an unsaturated aminocyclitol moiety, valienamine,
contained within their chemical structures (Shick and Dunlap 2002). Although, some of the class
members instead possess the epoxy, hydroxy or dihydro forms of valienamine (Mahmud 2003).
The common precursor to these metabolites is 2-epi-5-epi-valiolone, which is generated from
sedoheptulose 7-phosphate by the sugar phosphate cyclase, 2-epi-5-epi-valiolone synthase
(Mahmud 2009). Examples of C7N aminocyclitols include acarbose, salbostatin, cetoniacytone,
and validamycin (Figure 3.4) (Mahmud 2003). These members can be grouped based on the
stage of biosynthesis in which intermediate phosphorylation comes into play. In the acarbose
and salbostatin pathways, 2-epi-5-epi-valiolone is phosphorylated by a cyclitol kinase to 2-epi-5epi-valiolone 7-phosphate (Zhang, Stratmann et al. 2002). Alternatively, in validamycin and
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Figure 3.4. The C7N aminocyclitols. Shown are the chemical structures of various antibiotics
belonging to the C7N aminocyclitols class of natural products

cetoniacytone biosynthesis, 2-epi-5-epi-valiolone is not phosphorylated, but is instead first
epimerized to 5-epi-valiolone by a class of metalloproteins that appear to be a new type of αhydroxyketo-epimerases belonging to the Vicinal Oxygen Chelate (VOC) superfamily (Wu, Flatt
et al. 2007).
The C7N aminocyclitol family member, acarbose, is a pseudooligosaccharide isolated
from Actinoplanes, which contains an unsaturated cyclitol unit and a 4-amino-4,6dideoxyglucose unit. Acarbose potently inhibits sucrase, maltase, dextinase, and glycoamlyase
activity while also showing some inhibition activity against amylose degrading enzymes
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(Truscheit, Frommer et al. 1981). This clinically important α-glucosidase inhibitor has been
proven useful in the treatment of type II insulin independent diabetes by preventing digestion of
complex carbohydrates (Puls, Keup et al. 1977; Schmidt, Frommer et al. 1977). In September
1995 after years of availability in Europe, acarbose was approved by the FDA for use in the
United States as monotherapy in patients with non-insulin-dependent diabetes mellitus
(NIDDM).(Campbell, White et al. 1996)
Salbostatin is a basic, non-reducing pseudodisaccharide isolated from a fermentation
culture polyether antibiotic salinomycin producer, Streptomyces albus ATCC 21838. It consists
of valienamine linked to 2-amino-1,5-anhydro-2-deoxyglucitol (Vertesy, Fehlhaber et al. 1994).
Although salbostatin shows no antibiotic activity, it does effectively inhibit trehalase from
porcine kidney (Mahmud 2003).
Cetoniacytone is a metabolite isolated from an endosymbiotic Actinomyces sp. strain Lu
9419 that lives in the intestines of the rose chaffer beetle (Cetonia aurata) (Schlorke, Krastel et
al. 2002). The valienamine derived moiety of this unusual C7N aminocyclitol family member
contains an alkylated amino group at the C-2 position instead of an acetylated amino group at the
C-1 position as in most family members. The moiety also contains an epoxide. Despite the
structural anomalies, the core unit of cetoniacytone is derived via a product of the pentose
phosphate pathway, sedoheptulose 7-phosphate (Wu, Flatt et al. 2009).
Validamycin was first identified during the course of screening for new antibiotics at the
Takeda Chemical Company. Isolated from the fermentation culture of Streptomyces
hygroscopicus subsp. limoneus, this weakly basic, water-soluble antibiotic exhibited remarkable
therapeutic effects against plant diseases (Iwasa, Yamamoto et al. 1970; Iwasa, Higashide et al.
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1971). The biosynthesis of validamycin is of key interest in this document and is discussed in
greater detail in later sections.
Validamycin A
Early Uses of Validamycin A
Validamycin A is a pseudotrisaccharide found within certain species of Streptomyces
hygroscopicus and consists of valienamine and validamine connected via a nitrogen bridge. The
second cyclitol also carries a glucose monomer attached via a glycosidic link (Mahmud, Lee et
al. 2001). Validamycin A has long been used in the Far East as crop-protectant against ricesheath blight and the damping-off of cucumber seedlings caused by the pathogenic fungi
Rhizoctonia solani and Pellicularia sasakii, respectively (Iwasa, Yamamoto et al. 1970; Iwasa,
Higashide et al. 1971). The antifungal activity of validamycin A is brought about by its ability to
inhibit the enzyme trehalase. Trehalose is a disaccharide used chiefly within fungi as a
carbohydrate storage compound comprising about 8% of the dry weight of the biomass. The
administration of validamycin A results is an accumulation of toxic levels of trehalose
(Shigemoto, Okuno et al. 1992). This is observed as an abnormal branching of the tips of the
main hyphae and severe repression of the growing fungi (Shibata, Uyeda et al. 1981).
Validamycin has also been reported to have an adverse reaction on insects which is presumably
due to the similar prevalence of trehalose within some insects (Kameda, Asano et al. 1987). In
addition, the validamycin derivative, voglibose, is widely used as a treatment for diabetes (Horii,
Fukase et al. 1986). As a natural product with known biological importance, validamycin and its
derivatives are of great interest in agricultural and clinical research (Mahmud 2003).
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Discovery of the Validamycin A Gene Cluster
Acarbose is a compound used as a treatment for type II insulin-independent diabetes.
Acarbose works by preventing the proper catabolism of complex carbohydrates through the
inhibition of -glucosidases (Puls, Keup et al. 1977). A structural comparison to validamycin A
revealed that validamycin A and acarbose share an identical C7N aminocyclitol moiety,
valienamine (Mahmud 2003). The valienamine moiety of acarbose is known to originate from
the cyclization of sedoheptulose 7-phosphate to 2-epi-5-epi-valionone by AcbC, an enzyme
closely related to 3-dehydro-quinate synthases. Yu, Bai, et al. used the gene encoding AcbC
(abcC) within acarbose biosynthesis as a probe for genes encoding similar cyclization enzymes
within the genome of S. hygroscopicus subsp. limoneus (Yu, Bai et al. 2005). The localization of
the homologous gene valA allowed for the sequencing and analysis of a 45kb DNA fragment
containing the entire validamycin A biosynthetic gene cluster (Bai, Li et al. 2006). Homologous
validamycin A biosynthetic gene clusters have now been identified in two subspecies of
Streptomyces hygroscopicus, subsp. limoneus (vld) and subsp. jinggangensis (val) (Bai, Li et al.
2006; Singh, Seo et al. 2006). With the discovery of the validamycin A gene cluster, a
mechanistic analysis of validamycin A biosynthesis could begin in earnest.
Biosynthetic Pathway of Validamycin A
Despite the biosynthetic pathway not being elucidated in its entirety, the formation of
validamycin A by S. hygroscopicus is quite complicated. Both cyclitol components of
validamycin A are derivatives of 2-epi-5-epi-valionone, the common precursor to the various
C7N-aminocyclitol-containing natural products (Figure 3.5). 2-epi-5-epi-valionone is generated
by the cyclization of sedoheptulose 7-phosphate by the sugar phosphate cyclase, 2-epi-5-epivaliolone synthase ValA (VldA), a homolog of AcbC (Bai, Li et al. 2006). Within validamycin
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Figure 3.5. Early validamycin biosynthesis. Shown are the early enzymatic steps in the
biosynthesis of validamycin. (DH? Represents a currently unknown dehydrogenase)

A biosynthesis 2-epi-5-epi-valionone is then epimerized to 5-epi-valionone by ValD, a new type
of -hydroxyketo-epimerase belonging to the Vicinal Oxygen Chelate (VOC) superfamily (Bai,
Li et al. 2006; Xu, Zhang et al. 2009). Next is the dehydration of 5-epi-valionone to valienone
by a yet to be determined dehydratase. At this point, the editing of the two cyclitols diverges.
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ValC (VldC), a C7-cyclitol kinase, phosphorylates valienone to form valienone 7phosphate (Figure 3.6) (Minagawa, Zhang et al. 2007). The conversion of valienone 7phosphate to valienol 1-phosphate involves a stereoselective reduction of C-1, possibly by ValK,
followed by the transfer of phosphate from C-7 to C-1. The latter step may be catalyzed by a
phosphohexomutase, possibly ValO (Yang, Xu et al. 2011). Valienol 1-phosphate is
Nucleotidylated by ValB (VldB), a homolog of the sugar 1-phosphate nucleotidyltransferases
(Yang, Xu et al. 2011). The result is GDP-valienol, the first reactant in the in the condensation
reaction forming the precursory validoxylamine A 7´-phosphate.
In the production of validamine 7-phosphate, the second reactant of the condensation
reaction, valienone is most likely saturated by ValN (Figure 3.6). Although inconclusive, studies
show that inactivation of the putative cyclitol reductase gene valN prevents the synthesis of
validamycin A but instead produces unsaturated derivatives (Xu, Yang et al. 2009). The
resulting validone is then phosphorylated. The C7-cyclitol kinase, VldC (ValC), is also
responsible for the phosphorylation of this intermediate (Minagawa, Zhang et al. 2007).
Downstream, validone 7-phosphate may be recognized by the aminotransferase, ValM, to
produce validamine 7-phosphate (Bai, Li et al. 2006).
The pseudo-glycosyltransferase VldE(ValL) is responsible for the condensation of GDPvalienol and validamine 7-phosphate via a non-glycosidic nitrogen bridge to form
validoxylamine A 7´-phosphate (Figure 3.6) (Asamizu, Yang et al. 2011). The
dephosphorylation of validoxylamine A 7´-phosphate by VldH is necessary before the addition
of a glucose monomer by ValG (VldK) via a glycosidic linkage. ValG uses UDP-glucose as the
source for the carbohydrate (Bai, Li et al. 2006; Xu, Minagawa et al. 2008). The final addition
of the glucose monomer yields the natural antibiotic validamycin A.
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Figure 3.6. Late validamycin biosynthesis. Shown are the late enzymatic steps in the
biosynthesis of validamycin.
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Glycosyltransferases
A Large and Diverse Class of Enzymes
Within the biosynthetic pathway of validamycin, the enzyme VldE is of particular
interest because it mediates the condensation of the two aminocyclitol moieties via an amide
linkage. A sequential and functional analysis relates VldE to a family of enzymes known as the
glycosyltransferases (Bai, Li et al. 2006; Singh, Seo et al. 2006). The glycosyltransferases are an
extremely large and diverse class of enzymes found in every kingdom of life and in all cellular
compartments. Typically, they transfer a sugar residue from an activated donor to an acceptor.
The donor group is often a nucleotide sugar but there are examples of lipid phosphates and
sugar-1-phosphates (Hansen, Bettler et al. 2010). The nucleotide sugar –dependent
glycosyltransferases are often referred to as Leloir enzymes in honor of the 1970 Nobel Prize
laureate Luis F. Leloir for his contributions to glycobiology (Lairson, Henrissat et al. 2008). The
group of acceptors is also quite diverse, and the products of such reactions are
oligo/polysaccharides, glycoproteins, glycolipids, and many other glycosylated natural products
(Hansen, Bettler et al. 2010). The obvious abundance of this class of enzymes is seen in the
classification of glycosyltransferases by the CAZy database. The CAZy database divides the
91,000+ genes into 94 enzyme families (as of June 2012) (www.cazy.org) (Hansen, Bettler et al.
2010). In addition to classification based on amino acid sequence similarities, the
glycosyltransferases are generally distinguished by their three-dimensional folds which consist
primarily of Rossman-like // domains in either a GT-A or GT-B configuration. The GT-A or
GT-B folds are distinct from a sometimes associated transmembrane domain (Kikuchi and
Narimatsu 2006). Glycosyltransferases are further classified by the two possible stereochemical
outcomes for the formed glycosidic bond. The anomeric configuration of the donated moiety is
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either maintained or inverted in the product (Lairson, Henrissat et al. 2008). Recently,
glycosyltransferases not adopting a GT-A or GT-B topology have been reported, and sequence
searches have proposed a potential third topology, GT-C (Liu and Mushegian 2003; Lovering, de
Castro et al. 2007; Igura, Maita et al. 2008; Lizak, Gerber et al. 2011). As these cases are fairly
uncommon and as a complete verification of GT-C glycosyltransferases by experimental means
has not been performed (Lairson, Henrissat et al. 2008), the discussion of these “non-Leloir”
glycosyltransferases within this document will end here.
GT-A and GT-B Topologies
Unlike the diverse representatives of the 110 families of the glycosidases, only two folds
have been associated with the solved structures of the activated sugar-dependent
glycosyltransferases, GT-A and GT-B, with uncharacterized families also predicted to adopt one
of these two folds (Lairson, Henrissat et al. 2008). The GT-A fold, which consists of two
abutting // domains forming a single continuous core -sheet, was first described in SpsA
from Bacillus subtilis (Figure 3.7) (Charnock and Davies 1999).
SpsA is a glycosyltransferase implicated in the spore coat polysaccharide biosynthesis of
Bacillus subtilis (Stragier and Losick 1996). The N-terminal domain of SpsA consists of four
parallel -strands and two -helices forming a nucleotide-binding fold. The C-terminal domain
consists of a mixed -sheet flanked by three -helices forming an open groove which is the
likely binding site for the acceptor group (Charnock and Davies 1999). Because of the abutting
nature of the two Rossman-like domains, glycosyltransferases of the GT-A topology are often
considered as a single domain fold (Figure 3.7A). Additionally, most GT-A glycosyltransferases
contain an Asp-X-Asp signature responsible the coordination of the phosphate atoms of
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Figure 3.7. Glycosyltransferase topologies. Shown are ribbon diagrams representing the
crystallographic structures of enzymes demonstrating the two topologies associated with all
glycosyltransferases. (A) SpsA is of the GT-A topology while (B) -glucosyltransferase (GTB)
from T4-bacteriophage is of the GT-B topology.
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nucleotide donors through the coordination of a divalent cation, Mg2+ or Mn2+ (Hansen, Bettler et
al. 2010).
In comparison, the GT-B topology associated with glycosyltransferases features two
Rossman-like// domains oriented in an opposing, non-abutting manner. GT-B enzymes also
lack a coordinated divalent cation. There exists a strong conservation of the C-terminal
Rossman-like domain of GT-B enzymes, which has been associated with the binding
of nucleotides (Hansen, Bettler et al. 2010). The prototypical representative of the GT-B
glycosyltransferases is -glucosyltransferase (GTB) from T4-bacteriophage (Hansen, Bettler et
al. 2010). GTB is responsible for the glycosylation of doubled stranded DNA through transfer of
glucose from UDP-glucose to the hydroxymethyl substituents of modified cytosine bases as a
defense mechanism to prevent genome degradation by phage and host nucleases (Kornberg,
Kornberg et al. 1961). Structural studies revealed GTB to consist of two domains with similar
topologies with the active site located within the cleft separating the two domains. The Nterminal domains consisted of a seven stranded parallel twisted -sheet and seven -helices
while the C-terminal, nucleotide binding domain consists of a six stranded parallel twisted sheet and five -helices. The catalytic site is located at the interface of the two domains (Figure
3.7B) (Vrielink, Ruger et al. 1994).
Inverting Glycosyltransferases
Glycosyltransferases are further classified by the retention or inversion of the anomeric
configuration of the product with respect to the donor substrate. However there is no correlation
between the anomeric state of the reaction product and the fold topology as there are examples
both retaining and inverting reactions are catalyzed by both GT-A and GT-B folds (Lairson,
Henrissat et al. 2008).
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Figure 3.8. Catalytic mechanisms of glycosyltransferases. Shown are the various catalytic
mechanisms associated with glycosyltransferases: (A) an inverting SN2 reaction, (B) a retaining
double displacement SN2 reaction, and (C) a retaining SNi-like reaction.
The inversion of anomeric centers by glycosyltransferases works through a direct
replacement SN2-like reaction where the nucleophilic acceptor group displaces the activated
phosphate leaving group (Figure 3.8A). Such a mechanism can be directly inferred from the
catalytic mechanism of glycosidases. As the mechanistic strategy of inverting
glycosyltransferases is well understood, examinations of the catalytic mechanisms focus on the
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identification of the base catalyst and the method used to facilitate departure of the phosphate
leaving group (Lairson, Henrissat et al. 2008).
Inverting enzymes with a GT-A topology include SpsA, -1,4-galactosyltransferase, Nacetylglucosaminyltransferase I, -1,3-N-acetylglucosaminyltransferases, and
glucuronyltransferases (Lairson, Henrissat et al. 2008). Structural studies of these enzymes show
a conserved aspartate (or glutamate) within hydrogen bonding distance of the attacking hydroxyl
of the acceptor group which acts as a general base (Charnock and Davies 1999; Pedersen,
Tsuchida et al. 2000; Unligil, Zhou et al. 2000; Kakuda, Shiba et al. 2004; Jinek, Chen et al.
2006; Ramakrishnan, Ramasamy et al. 2006; Yang, Boze et al. 2009). Biochemical analysis
show that the divalent cation bound by most GT-A enzymes is necessary to facilitate the leaving
group by electrostatically stabilizing the forming negative charges on the phosphates of the
leaving group (Lairson, Henrissat et al. 2008). Although there are exceptions such as metal ionindependent sialyltransferases and β-1,6-GlcNAc transferases which use hydroxyls of basic
amino acids to stabilize the leaving group (Pak, Arnoux et al. 2006; Chiu, Lairson et al. 2007)
GT-B enzymes are more diverse in their selected modes of catalyzing glycosyl group
transfer (Lairson, Henrissat et al. 2008). The prototypical β-glucosyltransferase (BGT) from T4
bacteriophage is an inverting glycosyltransferase which uses aspartate as a general base with the
leaving group facilitated by positively charged side-chains. BGT does make use of a divalent
cation, but unlike GT-A enzymes, the cation is involved in product release not facilitation of the
leaving group (Lariviere and Morera 2002). The glycosyl transferases involved in the
biosynthesis of the peptide antibiotic vancomycin also use an aspartate as the catalytic base but
the leaving group is facilitated using a helix dipole and interactions with side chain hydroxyl and
imidazole groups (Mulichak, Losey et al. 2001; Mulichak, Losey et al. 2003; Mulichak, Lu et al.
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2004). The terpene/flavonoid glycosyltransferase UGT71G1, the flavonoid glucosyltransferase
VvGTI, the macrolide glycosyltransferases OleD and OleI, the human drug-metabolizing
glucuronyltransferases UGT2B7, and the bifunctional N- and O-glucosyltransferase from
Arabidopsis thaliana also use a similar metal ion-independent mechanism to facilitate leaving
group departure but the catalytic base was determined to be a histidine that interacts with an
adjacent carboxylate group (Shao, He et al. 2005; Offen, Martinez-Fleites et al. 2006; Bolam,
Roberts et al. 2007; Brazier-Hicks, Offen et al. 2007; Miley, Zielinska et al. 2007).
Retaining Glycosyltransferases
Similar to inverting glycosyltransferases, retaining glycosyltransferases are found within
both the GT-A and GT-B topologies. Unlike inverting glycosyltransferases, the catalytic
mechanism of retaining glycosyltransferases cannot be directly inferred from the reaction of
glycosidases. Glycosidases use a double-displacement SN2 reaction which works through a
covalently bound glycosyl-enzyme intermediate. In such a mechanism, the donor group
undergoes a nucleophilic attack by a nucleophilic residue which would displace the leaving
phosphate group and result in a glycosyl-enzyme intermediate with an inverted anomic center at
the donated group. This would be followed by a nucleophilic attack by the acceptor group which
would displace the nucleophilic residue and again invert the anomeric configuration of the
donated group resulting in a net retention of anomeric configuration of the donated group within
the product (Figure 3.8B) (Lairson, Henrissat et al. 2008).
The reaction mechanism of retaining glycosyltransferases is much less understood.
A double displacement mechanism has been implicated in some retaining glycosyltransferases.
For instance, the bovine galactosyltransferase, α3GalT, contains a carboxylate side-chain which
is correctly disposed to act as the nucleophile through the glycosyl-enzyme intermediate can be

72

formed. Mutation of this residue abolishes activity but activity can be rescued by azide
(Monegal and Planas 2006; Jamaluddin, Tumbale et al. 2007). However, most retaining
glycosyltransferases lack a candidate for this role in close proximity to the anomeric reaction
center and there is no strictly conserved signature within glycosyltransferase catalytic site to
suggest such a mechanism. Therefore two possibilities exist; either the catalytic site undergoes a
reorganization to provide an appropriate nucleophile candidate for a double displacement
reaction, or retaining glycosyltransferases work through an alternative mechanism (Lairson,
Henrissat et al. 2008).
A proposed alternative is a SNi-like single nucleophilic substitution (Figure 3.8C). A SNi
reaction is a special case SN1 reaction in which there is a partial decomposition of the donor
group generating partial yet discrete ion pairs. Within glycosyltransferase reactions, this ion pair
would be a partial negative charge on the leaving phosphate oxygen and a partial positive charge
on the anomeric carbon. This short-lived transition state would be completed by the association
with the attacking nucleophile of the acceptor group on the front-face of the anomeric carbon.
The formation of this immediate species occurs at a rate faster than that of solvent attack or the
reorganization required for the nucleophilic attack from the back-face of the anomeric carbon.
In such a mechanism, the leaving phosphate oxygen would also act as a general base to activate
the attacking nucleophile as it is the only moiety appropriately positioned to do so (Lairson,
Henrissat et al. 2008). Substrate/product phosphates are known to act as general bases and have
been implicated in the mechanisms of farnesyl diphosphate (FPP) synthases from Escherichia
coli and Trypanosoma cruzi (Hosfield, Zhang et al. 2004; Gabelli, McLellan et al. 2006).
Although SNi reactions have been proposed for both GT-A and GT-B topologies, the
facilitation of the leaving groups would occur through differing manners as seen in inverting
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glycosyltransferases. Retaining GT-A enzymes such as galactosyltransferase LgtC from
Neisseria meningitidis or rabbit muscle glycogenin use a divalent cation coordinated with the
Asp-X-Asp signature to facilitate the leaving group by stabilization of the forming negative
charges (Persson, Ly et al. 2001; Gibbons, Roach et al. 2002), while retaining GT-B enzymes
such as rabbit muscle glycogen phosphorylase (rmGP) and E. coli α-(1,3) glucosyltransferase
WaaG use positive side chains to facilitate the leaving group (Green, Cori et al. 1942; MartinezFleites, Proctor et al. 2006).
Oxocarbenium Ion-Like Transition State
Functional and sequential analysis of VldE suggests a mechanism analogous to that of
trehalose 6-phosphate synthase (OtsA). OtsA has been associated with a SNi-like mechanism.
The retaining glycosyltransferase reaction is stabilized by an oxocarbenium ion-like transition
state (Figure 3.8C) (Lairson, Henrissat et al. 2008). The aminocyclitol components of
validamycin lack the bridging oxygen found within a sugar moiety. So, the oxocarbenium ionlike transition state is not possible within aminocyclitol condensation by VldE. Perhaps, the
transition state of during VldE catalysis is stabilized by the olefinic moiety through a mechanism
similar to the formation of an oxocarbenium ion within OtsA (Asamizu, Yang et al. 2011).
Hopefully, structural studies of VldE can reveal the validity of the proposed mechanism.
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CHAPTER 4: MECHANISTIC INSIGHTS INTO VALIDOXYLAMINE A 7'PHOSPHATE SYNTHESIS BY VLDE USING THE STRUCTURE OF THE ENTIRE
PRODUCT COMPLEX
Introduction
Glycosyltransferases comprise one of the most numerous and diverse groups of enzymes
in nature. They are responsible for the formation of oligo/polysaccharides, glycoproteins,
glycolipids, and many other glycosylated natural products by transferring a sugar moiety from an
activated donor sugar to a sugar (or non-sugar) acceptor. This abundant group of proteins
consists of 92 families encoded by more than 83,400 genes.(Hansen, Bettler et al. 2010)
However, only a fraction of those genes has actually been functionally characterized. Our
comparative bioinformatics studies suggest that among those reported as glycosyltransferases are
also pseudo-glycosyltransferases (such as VldE), which do not recognize sugars as substrates but
rather catalyze the formation of non-glycosidic C-N bonds in the biosynthesis of C7Naminocyclitol-containing natural products such as acarbose and validamycin A (Figure 4.1).(Bai,
Li et al. 2006; Singh, Seo et al. 2006; Asamizu, Yang et al. 2011) Acarbose, an -glucosidase
inhibitor, has been proven useful in the treatment of type II insulin-independent diabetes,
whereas validamycin A, a natural trehalase inhibitor, is an antifungal antibiotic that has long
been used to protect crops from soil borne diseases such as rice sheath blight and the dumpingoff of cucumber seedlings.(Iwasa, Yamamoto et al. 1970; Iwasa, Higashide et al. 1971; Xia and
Jiao 1986; Mahmud 2003)
Validamycin A is a pseudo-trisaccharide whose structure is comprised of validoxylamine
A and glucose (Figure 4.1). The final step in validamycin A biosynthesis is the attachment of
glucose to the precursory validoxylamine A by the action of the glycosyltransferase VldK
(ValG).(Bai, Li et al. 2006; Xu, Minagawa et al. 2008) Validoxylamine A is generated through
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Figure 4.1. The VldE and OtsA reactions. This figure was prepared with ChemBioDraw
(ChemBioDraw Ultra 10.0 CambridgeSoft, 100 Cambridge Park Drive, Cambridge, MA 02140).
The product and substrates of the VldE and OtsA catalyzed reactions are shown. Note the
considerable similarity between the ligands of VldE and OtsA, and the conservation of the
anomeric centers. The biosynthetic products of both the completed enzymatic pathways are also
shown. VldE catalyzes the formation of validoxylamine A 7´-phosphate via a non-glycosidic CN bond between GDP-valienol and validamine 7-phosphate. After the validoxylamine A 7´phosphate has been produced; VldH and VldK complete the catalytic synthesis of Validamycin
A. OtsA catalyzes the formation of trehalose 6-phosphate via a glycosidic bond between UDPglucose and glucose 6-phosphate. OtsB dephosphorylates trehalose 6-phosphate to produce
trehalose.
the dephosphorylation of validoxylamine A 7´-phosphate by VldH while validoxylamine A 7´phosphate (VDO) results from a condensation of GDP-valienol and validamine 7-phosphate
(both are pseudo-sugars) by the pseudo-glycosyltransferase, VldE.(Mahmud, Lee et al. 2001;
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Wehmeier and Piepersberg 2004; Seo, Im et al. 2006; Singh, Seo et al. 2006; Flatt and Mahmud
2007; Mahmud 2009; Asamizu, Yang et al. 2011)
The mechanism by which non-glycosidic C-N bond is formed by a pseudoglycosyltransferase is not entirely understood. However, because of the structural similarity of
validoxylamine A 7´-phosphate to trehalose 6-phosphate (Figure 4.1), it has been speculated that
the mechanism of the pseudo-glycosyltransferase VldE is similar to that of the
glycosyltransferase, trehalose 6-phosphate synthase (OtsA).(Asamizu, Yang et al. 2011) VldE
and Escherichia coli OtsA only share a modest 19% sequence identity (29% homology) (Figure
4.2), but they are both catalogued as members of the GT20 glycosyltransferase family by the
CAZy database (www.cazy.org).(Coutinho, Deleury et al. 2003) OtsA mediates the transfer of
glucose moiety from UDP-glucose to glucose 6-phosphate to form trehalose 6-phosphate (Figure
4.1). Similar to VldE, the product of OtsA conserves the anomeric configuration of the donor
moiety. Glycosyltransferases have been shown to both retain and invert the anomeric state of the
carbon C-1 of the donor moiety. The inversion of the anomeric center by glycosyltransferases
has been well explored and is known to be carried out by a simple nucleophilic substitution.
However, the net retention of the anomeric center is much more ambiguous, but it is thought to
occur through either a double displacement (SN2 X2) or internal return mechanism
(SNi).(Lairson, Henrissat et al. 2008) For a double displacement nucleophilic substitution
reaction to occur, a nucleophilic catalytic base must be available in close vicinity to the sugar
anomeric carbon to form a covalent intermediate. OtsA apparently lacks such a residue in the
catalytic site and analyses of theoretical energy manifolds along with recent studies of kinetic
isotope effects have substantiated this unusual enzymatic reaction mechanism within
OtsA.(Gibson, Turkenburg et al. 2002; Tvaroska 2006; Lee, Hong et al. 2011) Lastly, structural
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Figure 4.2. An alignment of VldE and OtsA. Shown is the protein sequence alignment of
VldE and OtsA as generated by ClustalW2.(Larkin, Blackshields et al. 2007) Residues whose
side-chains are involved in ligand binding are indicated with shaded boxes. Conserved residues
are indicated with unfilled boxes. The two-dimensional secondary structure of VldE and OtsA
are also illustrated next to the corresponding sequence with -helices represented by spirals and
-strands represented by arrows. Numerical values for helices and strands are assigned.
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studies of OtsA, using a bi-substrate inhibitor as a product mimic, place the atoms involved in
catalysis in an orientation favorable for an internal return mechanism and show that the leaving
phosphate acts as a general base to deprotonate the incoming nucleophile of the acceptor
group.(Errey, Lee et al. 2010) The SNi mechanism of OtsA works through an oxocarbenium ionlike transition state.(Errey, Lee et al. 2010; Lee, Hong et al. 2011) However, no oxocarbenium
ion formation is possible in the VldE-catalyzed non-glycosidic C-N coupling reaction.
Alternatively, it is proposed that the olefinic moiety of GDP-valienol may play a critical role in
facilitating the coupling reaction.(Asamizu, Yang et al. 2011) Coupling reactions involving an
allylic moiety have been demonstrated in other biosynthetic enzymes, e.g., farnesyl diphosphate
(FPP) synthases.(Kellogg and Poulter 1997; Thulasiram and Poulter 2006) However, in FPP
synthases, a nucleophilic substitution reaction takes place at a carbon center with a diphosphate
acting as a leaving group instead of nucleotidyl diphosphate. In addition, mechanistically FPP
synthases adopt a stereospecific SN1 reaction with an inversion of the configuration, leaving the
actual mechanism behind the unique catalytic function of the retaining VldE enzyme unclear.
Hopefully, structural studies would clarify whether or not a SNi mechanism is conserved within
the retaining pseudo-glycosyltransferase, VldE.
Here, we report the three-dimensional structures of VldE in various liganded states using
crystallographic techniques. The structure of VldE was solved by molecular replacement using
the structure of OtsA as a search model. We have elucidated the structures of the unliganded
VldE, in complex with guanosine 5´-diphosphate (GDP), in complex with GDP and Trehalose
(TRE), and in complex with GDP and VDO. Similar to OtsA, VldE is comprised of two
Rossman // domains which are oriented in a GT-B configuration (Figure 4.3). The active
site, which is located at the interface of the Rossman domains, and the selective interactions
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Figure 4.3. The overall fold of VldE. All protein renderings were constructed using PyMOL
(The PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, and LLC.). Shown is
the overall fold of VldE as well as comparison to OtsA by superimposition. (A) The overall fold
of the monomeric VldE is represented in a ribbon diagram. The monomer is rendered with the
N-terminal domain in red, and the C-terminal domain in blue. The -helical C-terminus, which
stretches back across both domains, is rendered in green. VldE consists of twin Rossman-like
// domains in a GT-B configuration with the catalytic site marked by VDO and GDP at the
interface of the two domains. (B) To compare the overall fold of VldE (green) to OtsA (gray),
the folding patterns, which were represented by a tracing of C-alphas, were superimposed within
a wall-eye stereo image.
allowing for the binding of GDP but not uridine 5´-diphosphate (UDP) are described in our study
(Figure 4.4A-B). The crystallographic investigation of VldE while binding the complete product
complex, VDO and GDP, supports the proposed conservation of a SNi catalytic mechanism
analogous to the mechanism of OtsA. Both the “open” and “closed” conformations of the
catalytic site are also described within this study.
Materials and Methods
Purification and Crystallization
VldE from S. hygroscopicus subsp. limoneus was expressed and purified with methods similar to
those previously described.(Asamizu, Yang et al. 2011) 6XHis-tagged VldE was expressed in E.
coli BL21 (DE3) pLysS and was purified using Ni-NTA affinity chromatography. Affinity
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Figure 4.4. The catalytic site. Shown is a comparison of the VldE and OtsA catalytic sites in
ribbon diagrams. Residues/molecules of interest are represented in stick models. The dotted
lines mark significant interactions. The preferential binding of GDP by VldE is demonstrated
by comparing (A) the protein-ligand interactions within the VldE active site (green) with (B) the
protein-ligand interactions between OtsA and UDP within the OtsA active site (gray). The
protein interactions with ribose and phosphate are conserved between VldE and OtsA. However,
there are differing interactions with the nucleotide base groups. The large purine makes
interactions with the residues Arg321, Asn323, Asn361, and Thr366. The ribose and phosphate
moieties interact with Arg290, Lys295, Leu387, Ser388, and Glu391. Within OtsA, Leu344,
Ile295, Pro297, and His338 only allow for the binding of the smaller pyrimidine. The ribose and
phosphate moieties make interactions with residues Arg262, Lys267, Leu365, and Glu369. The
mesh represents the |Fo| -|Fc| electron density omit map of the GDP binding site. The map is
contoured at 3.0 levels. (C) Shown is a superimposition of the VldE cyclitol binding sites in the
presence (yellow) and absence (green) of validoxylamine A 7´-phosphate. The mesh represents
the |Fo| -|Fc| electron density omit map of the VDO binding site. The map is contoured at 3.0
levels. VDO makes interactions with residues the side-chains of residues Asp158, His182,
Arg12, Asn325, Arg326, and Asp383. VDO also makes interactions with the backbones of
residues 384-387. Binding of the acceptor cyclitol is recognized by conformation changes by the
side-chains of residues Asp158, Tyr159, and Arg326. (D) Shown is a comparison by
superimposition of VDO binding within the catalytic sites of VldE (yellow) and OtsA (gray).
Note the strong conservation of residue and ligand positions.
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chromatography was performed using 40mM Hepes buffer, pH 7.5 with 300mM NaCl, 20mM
imidazole, 5mM -mercaptoethanol, and 10% glycerol. Elution from the Ni-NTA resin was
achieved using the same buffer but with 175mM imidazole. Using dialysis, the affinity
chromatography buffer was exchanged with VldE storage buffer consisting of 10mM Tris-HCl,
pH 7.5 with 5% glycerol, 0.1mM dithiothreitol, and 1mM MgCl2. VldE was concentrated to
10mg/mL, and crystals were grown using sitting drop vapor diffusion.
In the case of VldE and VldE•GDP crystals, the mother liquor consisted of 100mM TrisHCl, pH 8.0 with 30-35% polyethylene glycol 3,350. GDP, at a concentration of 3mM, was
added to protein stocks which were intended to grow VldE•GDP crystals by co-crystallization.
Crystals with a size of 0.1 X 0.1 X 0.5 mm were grown over a period of four to twelve weeks.
Crystallization took place at a temperature of 293K. Cryoprotectant solutions, consisting of
artificial mother liquor enriched with 20% ethylene glycol, were added to crystal drops at a
1:1(v/v) ratio. In the case of VldE•GDP crystals, 5mM GDP was added to the cryoprotectant
solution. Crystals were flash-cooled in liquid nitrogen after soaking in the cryoprotectant
solution for 20-40 minutes.
In the case of VldE•GDP•VDO crystals, the mother liquor consisted of 100mM Tris-HCl,
pH 8.0 with 25-30% polyethylene glycol 3,350. The drop was formed through a mixture of
mother liquor, protein, and seed stock in a ratio of 1.6:2.0:0.4 (v/v). Seed stocks were prepared
from crystal grown in similar conditions using Seed Beads (Hampton Research) in a stabilization
buffer of 100mM Tris-HCl, pH 8.0 with 31% polyethylene glycol 3,350. The Crystals with a
size of 0.1 X 0.1 X 0.5 mm were grown over a period of four to twelve weeks at a temperature of
293K. Cryoprotectant solutions, consisting of artificial mother liquor enriched with 20%
ethylene glycol, were added to crystal drops at a 1:1(v/v) ratio. 5mM GDP and 10mM VDO
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were added to the cryoprotectant solutions. Crystals were flash-cooled in liquid nitrogen after
soaking in the cryoprotectant solution for 20-40 minutes.
In the case of VldE•GDP•TRE crystals, the mother liquor consisted of 50mM Tris-HCl,
pH 8.0, 18-28% polyethylene glycol 3,350, 200-500mM NaCl, and 20mM MgCl2. VldE was
kept at a concentration of 10mg/mL, and crystals were grown using sitting drop vapor diffusion
with a 1:1(v/v) mixture of protein and mother liquor. Before the drops were set, 3% trehalose
and 1mM GDP were added to the protein stocks. The Crystals with a size of 0.1 X 0.1 X 0.1 mm
were grown over a period of four to eight weeks at a temperature of 293K. Cryoprotectant
solutions, consisting of reservoir solution enriched with 20% ethylene glycol, 3% trehalose, and
1mM GDP were added to crystal drops at a 1:1(v/v) ratio. Crystals were flash-cooled in liquid
nitrogen after soaking in the cryoprotectant solution for 20-40 minutes.
Data Collection and Processing
All diffraction data except for the VldE•GDP dataset was collected at the Northeastern
Collaborative Access Team (NE-CAT) beamline at the Advanced Photon Source (Argonne
National Laboratory). Data was recorded at 100K on an ADSC Q315 (315mm X 315mm)
detector and processed by NE-CAT's RAPD automated processing
(https://rapd.nec.aps.anl.gov/rapd), which uses XDS (Kabsch 2010) for integration and scaling.
A 2.0Å VldE dataset was collected at a wavelength of 0.9479 Å while oscillating the crystal 0.5
degrees for each frame. A 2.11Å VldE•GDP•VDO dataset was collected at a wavelength of
0.9792 Å while oscillating the crystal 1.0 degrees for each frame. A 2.81Å VldE•GDP•TRE
dataset was collected at a wavelength 0.9792Å while oscillating the crystal 1.0 degrees for each
frame. The 2.15Å VldE•GDP dataset was collected at NSLS Beamline X6A at a wavelength
1.0Å while oscillating the crystal 1.0 degrees for each frame. X-ray data was collected on a

84

ADSC Quanta CCD detector at 100K and was integrated, merged, and scaled using
HKL2000.(Otwinowski and Minor 1997) Although the cell dimensions were similar, the
unliganded VldE crystal belonged to the P2 space group, while the VldE•GDP and
VldE•GDP•VDO crystals belonged to the P21 space group. The unit cell dimensions of the
VldE•GDP•TRE dataset were dissimilar and belonged to the C2 space group. Diffraction data
statistics are summarized in Table 4.1.
Structure Determination and Refinement
To determine the structure of VldE, molecular replacement (MR) was performed.
Generation of a search model from the OtsA structure (PDB accession code 1UQU (Gibson,
Tarling et al. 2004)) and molecular replacement was carried out using MrBUMP (Keegan and
Winn 2007) to orchestrate molecular replacement via the MOLREP (Vagin and Teplyakov 1997)
module in the CCP4 (Collaborative Computational Project 1994) program suite. The resulting
MR model was used to build a partially sequenced model (~400 residues) using the
AUTOBUILD (Terwilliger 2004; Afonine, Grosse-Kunstleve et al. 2005; Terwilliger, GrosseKunstleve et al. 2008; Terwilliger, Grosse-Kunstleve et al. 2008) function of the PHENIX
(Adams, Afonine et al. 2010) software suite. Further automated model building was carried out
using the ARP/wARP (Langer, Cohen et al. 2008) module within the CCP4 (Collaborative
Computational Project 1994) software suite. The model was finished by manual building within
COOT (Emsley, Lohkamp et al. 2010). The model was refined using restrained refinement by
REFMAC5 (Vagin, Steiner et al. 2004) with TLS parameters defined by the TLSMD
server.(Painter and Merritt 2006; Painter and Merritt 2006) Two monomers were modeled
within the asymmetric unit, and non-crystallographic symmetry (NCS) restraints were used
during refinement. Waters were incorporated into the models by referring to the |Fo|-|Fc| omit
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Table 4.1. Statistics of reflection data and structure refinements (VldE).
Liganding
VldE
VldE•GDP
Space Group
P2
P21
Unit Cell Dimension (Å)
84.75 X 48.43 X
47.82 X 121.15
122.66
X 84.33
91.88
91.74
Unit Cell -angles(°)
Wilson Plot B Value (Å2)
48.74
35.96
Resolution Range (Å)
48.92-1.95
37.52-2.15
Reflections Observed
245,918
368,911
Unique Reflections
69,317
51,924
Reflections Rfree Set
3,559
2,645
Completeness (%)
98.1 (91.8)
99.9 (100.0)
Redundancy
3.5 (3.3)
7.1 (7.1)
13.0 (2.7)
25.2 (3.1)
<I/>
Rsym
0.045 (0.421)
0.078(0.522)
Rwork
0.190
0.197
Rfree
0.222
0.209
No. TLS Bodies
6
n/a
No. of Amino Acids
957
948
No. of Protein Atoms
7,474
7,378
No. of Hetero Atoms
0
58
No. of Waters
492
405
R.M.S.D Bond Lengths (Å)
0.022
0.012
Angles (°)
1.67
1.30
Mean B Factor
41.85
40.21
Protein Atoms (Å2)
42.63
40.19
2
Hetero Atoms (Å )
n/a
34.34
Water Atoms (Å2)
29.38
40.93
Ramachandran Outliers (%)
0.5
0.4
Ramachandran Favored (%)
97.8
97.8
Poor Rotamers (%)
1.6
1.3
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VldE•GDP•VDO
P21
47.96 X 120.71
X 84.24
91.63
40.37
47.94-2.11
205,530
55,049
2,790
99.7 (99.0)
3.7 (3.7)
16.5 (2.7)
0.049(0.433)
0.191
0.222
n/a
950
7,361
120
488
0.017
1.76
39.62
39.59
37.63
40.50
0.4
97.3
1.6

VldE•GDP•TRE
C2
320.82 X 122.82
X 93.86
91.62
53.40
49.15-2.81
220,052
88,243
4,421
99.3 (98.5)
2.5 (2.5)
12.2 (2.7)
0.058(0.304)
0.211
0.258
n/a
2,738
21,796
214
202
0.016
1.47
62.41
62.61
62.57
40.82
0.4
95.5
1.5

Table 4.1 continued
Rsym = Σ h(Σ j|Ihj - <Ih>|/ Σ Ih,j), where h=set of Miller indices, j=set of observations of reflection h, and <Ih>=the mean
intensity. R.M.S.D. values are deviation from ideal values. Rcrys= Σh||Fo,h| – |Fc,h||/ Σh|Fo,h|. Rfree was calculated using
5% of the complete data set excluded from refinement. The numbers in parentheses represent values from the highest
resolution shell (2.08-2.00Å for VldE, 2.23-2.15Å for VldE•GDP, 2.22-2.11Å for VldE•GDP•VDO, and 2.96-2.81Å
for VldE•GDP•TRE).
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maps. Out of the possible 994 residues, 957 residues were modeled with 97.8% within the most
favored regions of the Ramachandran plot. Although 0.5% are reported as outliers, they are all
within well-defined electron densities. The final model, which lacked residues 1, 2, and 482497, has a Rwork of 0.190 and an Rfree of 0.222. The structure refinement statistics are
summarized in Table 4.1.
The VldE•GDP, VldE•GDP•VDO, and VldE•GDP•TRE structures were solved using the
unliganded VldE structure as a search model within the AUTOMR (Mccoy, Grosse-Kunstleve et
al. 2007) function of the PHENIX (Adams, Afonine et al. 2010) software suite. The models
were finished by manual building within COOT.(Emsley, Lohkamp et al. 2010) The models was
refined the PHENIX.REFINE (Afonine, Grosse-Kunstleve et al. 2005) function of the PHENIX
(Adams, Afonine et al. 2010) software suite. Ligands and waters were incorporated into the
models by referring to the |Fo|-|Fc| omit maps.
Within the VldE•GDP structure, two monomers were modeled within the asymmetric
unit, and NCS restraints were used during refinement. Out of the possible 994 residues, 948
residues were modeled with 97.8% are within the most favored regions of the Ramachandran
plot. Although 0.4% are reported as outliers, they are all within well-defined electron densities.
Within the VldE•GDP•TRE structure, six monomers were modeled within the
asymmetric unit, and NCS restraints were implemented during refinement for polypeptide chain
pairs A and D, B and E, and C and F. Out of the possible 2,982 residues, 2,738 residues were
modeled with 95.5% within the most favored regions of the Ramachandran plot. Although 0.4%
are reported as outliers, they are all within well-defined electron densities.
Within the VldE•GDP•VDO structure, two monomers were modeled within the
asymmetric unit, and NCS restraints were used during refinement. Out of the possible 994
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residues, 950 residues were modeled with 97.3% within the most favored regions of the
Ramachandran plot. Although 0.4% are reported as outliers, they are all within well-defined
electron densities.
The Ramachandran outliers at residues Asp158 and Asn386 were common within all the
monomers of all the models of VldE.
Diffraction and structure refinement statistics are summarized in Table 4.1. Coordinates
and structure factors have been deposited in the Protein Data Bank with accession numbers:
VldE (PDB ID: 3VDM), VldE•GDP (PDB ID: 4F96), VldE•GDP•VDO (PDB ID: 4F97), and
VldE•GDP•TRE (PDB ID: 4F9F).
Results
Overall Structure
As was recently described in a crystallographic study of ValL (identical but for a four residue
insertion) (Zheng, Zhou et al. 2012), a VldE homolog from S. hygroscopicus subsp.
jinganggensis, VldE consists of twin Rossman // domains in the GT-B configuration
(Vrielink, Ruger et al. 1994) (Figure 4.3A) with the terminal helix (16) extending back across
the C-terminal Rossman-like domain to reach the N-terminal Rossman-like domain with a turn at
Trp458 as it crosses the interface of the two domains. Despite a modest 19% sequence identity
(29% homology) (Figure 4.2), the overall fold of VldE is remarkably similar to OtsA (Figure
4.3B), a fellow member of the GT20 family. Unlike the previous study however, the core of the
N-terminal domain of our apo enzyme is found with the catalytic site in an “open” conformation
instead of “closed”. In this “open” conformation, the core -sheet of the N-terminal Rossmanlike domain consists of only ten strands instead of twelve. Two strands described as part of the
core sheet in the previous study now are observed in a unique -hairpin motif (2 and 3)
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extending away from the catalytic site. Simultaneously, there is a dramatic shift of residues 3347 away from the catalytic center. Unfortunately, coordinates from the structural study of ValL
were not publicly available at the time of this study, so a complete comparison could not be
performed. However, the closed conformation of VldE will be described in later sections of this
article using our own experimental data.
The GDP bound structure of VldE (VldE•GDP) described here is also in an “open”
conformation and the binding of GDP did not have an effect on the global conformation of the
apo enzyme (R.M.S.D. of C = 0.350). Surprisingly, the structure of VldE in complex with the
entirety of its products (VldE•GDP•VDO), GDP and VDO was also in an open conformation and
a comparison to the VldE•GDP model showed that the binding of VDO also did not have an
effect of the global conformation of VldE (R.M.S.D. C = 0.262).
Lastly, we also elucidated the structure of VldE in complex with both GDP and TRE
(VldE•GDP•TRE). Within the VldE•GDP•TRE structure, six monomers were modeled within
the asymmetric unit (ASU). The six monomers of the ASU assumed three alternative
conformers. The monomers of the first conformation contained both GDP and trehalose, and this
first conformer was found to also have an “open” catalytic site with similar global conformation
to the VldE•GDP•VDO complex (R.M.S.D. C = 0.705). The last two conformers within the
VldE•GDP•TRE structure had GDP but not trehalose bound, and these two conformers contained
a “closed” catalytic site as described in the previous studies.(Zheng, Zhou et al. 2012) These
alternative conformations, which have significant differences when compared the open
VldE•GDP structure also described here (R.M.S.D. C = 2.304, R.M.S.D. C = 2.395), are
further discussed in later sections.
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The Nucleotide Binding Site
Due to the conservation of key residues within their binding pockets, the binding of ligands
within VldE are thought to be analogous to OtsA.(Gibson, Turkenburg et al. 2002) Here we
provided experimental support for the analogous binding of GDP within VldE and UDP within
OtsA. (Figure 4.4A) Within VldE, the ribose and phosphate moieties of GDP make interactions
with the side-chains of the residues Arg290, Lys 295 and Glu391; as well as with the backbone
atoms of residues Leu387 and Ser388 (Figure 4.5A). These interactions are conserved within
OtsA (Figure 4.4B). The -phosphate of GDP does make a single unique interaction with
Ser388 within VldE. This interaction is not possible within OtsA as there is a valine at the same
position. Nonetheless, the ribose and phosphate moieties of GDP within the VldE catalytic
pocket are near perfectly superimposable onto the ribose and phosphate moieties of UDP within
the OtsA catalytic pocket. The conserved position of the -phosphate of GDP is critically
important because the bond between this phosphate and the donated cyclitol is broken during the
transfer to the acceptor. As will be described later in this study, the -phosphate of GDP
maintains an interaction with the anomeric carbon of validoxylamine A 7´-phosphate in the
complete product complex (VldE•GDP•VDO). This interaction is similarly found within OtsA
and similarly provides strong evidence in support of an SNi mechanism.(Lee, Hong et al. 2011)
The guanine moiety within the VldE•GDP complex makes interactions with the
hydrophilic residues Arg321, Asn323, and Thr366 (Figure 4.5A). A comparison to the binding
of a uracil moiety of the nucleotide activated donor sugar within OtsA allows an immediate
understanding of the preferential binding of the guanine moiety by VldE. The preference of
guanine by VldE is mediated by these three hydrophilic residues, while the preference for a
uracil moiety is mediated by three hydrophobic residues at the same positions. Within OtsA, the
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Figure 4.5. Ligand interactions. Shown is a ChemBioDraw figure showing the hydrogen bond
network between VldE and (A) GDP and then (B) VDO.
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uracil is surrounded by the hydrophobic residues Ile295, Pro297, and Leu344. This small
hydrophobic binding pocket facilitates the binding of a uracil moiety. Interactions between VldE
and GDP are summarized in Table 4.2.
Cyclitol Binding Sites
Provided within this article is the first structure of VldE in complex with the true
products of its catalyzed reaction, VDO and GDP (Figure 4.4C). The interactions between GDP
and VldE are described within the previous section, but here the interactions between VDO and
VldE are shown to be analogous to the interactions previously described by the OtsA•VDO
complex.(Errey, Lee et al. 2010) The hydroxyls of the donated cyclitol make numerous
interactions with the backbone amides of VldE at residues Gly384, Gln385, Asn386, and
Leu387. The donated cyclitol also makes interactions with the side-chains of residues His182
and Asp383 (Figure 4.5B). The interactions by donated cyclitol are conserved within the
catalytic site of OtsA (Figure 4.4D). Also conserved is the interaction of the -phosphate with
the anomeric carbon of the donated cyclitol. As in OtsA, the phosphate of the leaving nucleotide
is involved in the stabilization of the transition state during the concerted, front-faced
nucleophilic attack of a SNi reaction, and at a distance of 2.6Å from the attacking nucleophile,
the phosphate can act as a general base to deprotonate the amine.(Errey, Lee et al. 2010)
The binding of the acceptor cyclitol within VldE is recognized by a shift in side-chain
conformations within the catalytic site. Asp158 swings about 62-83° towards the catalytic center
in recognition of the hydroxyls of the acceptor cyclitol. Upon the binding of the phosphorylated
acceptor group, the guanidine moiety of Arg326 enters into an interaction with the phosphate
oxygens. This interaction allows Tyr159 to swing about 110-112° to make an interaction with
Arg326. The acceptor cyclitol also interacts with the side-chain of Asn325. These interactions
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Table 4.2. Notable interactions between VldE and ligands.
GDP
Protein Atom
Arg321*
Asn323*
Asp360
Asn361
Asp362
Thr366*
Arg290
Lys295
Leu387
Ser388
Glu391
His182
Asp383
Gly384
Gln385
Asn386
Leu387

Guanine
NH2
ND2
ND2
O
OD1
OD1
N
O
OG1
OG1
NE
NH2
NZ
NZ
N
N
OG
N
OE1
OE2
ND1
OD1
N
N
N
N
N
N

Ribose 5’phosphate

Validoxylamine A
7´-Phosphate
Donor
Acceptor
Cyclitol
Cyclitol-P

Trehalose
Donor
Sugar

O6 (3.3)
N1 (3.3)
N2 (3.4)
O6 (3.3)
N1 (2.6)
N2 (2.9)
O6 (2.9)
O6 (3.2)
N7 (2.6)
O6 (3.6)
O2B (2.8)
O1B (2.9)
O3A (3.1)
O1B (3.0)
O1A (3.4)
O2A (2.8)
O1A (2.6)
O1A (3.1)
O2’ (2.5)
O3’ (2.6)
OAQ (2.8)
OAS (2.9)
OAS (3.0)
OAS (2.7)
OAR (2.8)
OAS (3.4)
OAR (2.7)
OAR (3.6)
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O6P (3.7)
O3P (3.3)
O3P (2.6)
O3P (2.2)
O4P (3.2)
O3P (3.4)
O4P (2.6)
O4P (3.7)

Acceptor
Sugar

Table 4.2 continued.
Asp158
OD1
OAO (3.3)
OD2
OAP (2.3)
Asn325
ND2
OAX (2.4)
OD1
OAX (3.6)
Arg326
NH1
OAW (3.0)
NE
OAY (3.6)
Arg290
NE
Values in parentheses are distances given in angstroms.
Donor/Acceptor is an indicator of relative position within the catalytic site.
Distances describing GDP interactions with VldE are taken from the VldE•GDP model.
* Indicates residues not conserved in OtsA that make guanine specific interactions.
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O4 (3.7)

are conserved within OtsA except at Asn325. At the same position within OtsA there is Ser299
which does not make an interaction with VDO (Figure 4.4D).(Asamizu, Yang et al. 2011)
Despite the conservation of the interactions between the catalytic site and VDO, there is
no observed conformational closing of the catalytic site upon the binding of the acceptor cyclitol
as was witnessed in structural studies of OtsA.(Gibson, Turkenburg et al. 2002; Gibson, Tarling
et al. 2004; Errey, Lee et al. 2010) However, a closed conformation was described in the
recently published structural studies of ValL.(Zheng, Zhou et al. 2012) In later sections, such a
conformational shift will be described within our structural studies of VldE, but this shift was not
triggered by the binding of the acceptor cyclitol.
We were also able to elicit the structure of VldE in complex with both GDP and trehalose
(VldE•GDP•TRE). (Figure 4.6A) Within this model, GDP maintains the interactions previously
described elsewhere within this study. The binding pose of trehalose is similar to what was
described by the recent structural study of VldE.(Zheng, Zhou et al. 2012) The sugar moiety of
trehalose within donor cyclitol binding site makes interactions with the backbone amides of
residues Gly384, Gln385, Asp386, and Leu387 as well with the side-chains of Asp383 and
His182. Unsurprisingly, this conserves the interactions between the enzyme and the structurally
similar donor cyclitol as was described in the VldE•GDP•VDO model. However, the sugar
moiety of trehalose occupying the acceptor cyclitol binding site makes only a single significant
interaction with Arg290 in our study. A superimposition of trehalose and VDO within the VldE
catalytic site shows that trehalose does not assume a binding pose comparable to VDO (Figure
4.6B). This is most likely due to the absence of a phosphorylated ligand. Within the
VldE•GDP•VDO model, Arg326 and Asn325 interact with the phosphorylated cyclitol and most
likely help to ensure the proper docking of validamine 7-phosphate for catalysis. Indicatively,
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Figure 4.6. Trehalose within the catalytic site. Shown is a trehalose (TRE) within the VldE
cyclitol binding site in ribbon diagrams. Residues/molecules of interest are represented in stick
models. The dotted lines mark significant interactions. (A) The mesh represents the |Fo| -|Fc|
electron density omit map of trehalose within the VldE catalytic site (pink). The map is
contoured at 3.0 levels. Trehalose makes interactions with the backbone amides of residues
Gly384, Gln385, Asp386, and Leu387 as well with the side-chains of Asp383, His182 and
Arg290. (B) Shown is a superimposition of the catalytic sites of VldE•GDP•VDO model
(yellow) and the VldE•GDP•TRE model (pink) in ribbon diagrams. Trehalose does not assume a
binding pose comparable to VDO. This is most likely to do the absence of a phosphorylated
ligand as Arg326 and Asn325 swing out of the catalytic site.
Arg325 and Asn326 swing out of the catalytic site within our trehalose bound structure.
Interactions between VldE and VDO and TRE are summarized in Table 4.2.
Observed Changes in Conformation
While solving the VldE•GDP•TRE structure, six monomers of VldE were placed within
the asymmetric unit. Represented within the six monomers were three differing conformations
of the N-terminal Rossman-like domain (two monomers per conformation). (Figure 4.7A-C)
The first conformer had GDP and trehalose bound and is described in the previous
section. This conformer is quite similar to the other models with “open” catalytic sites expect for
residues 325-328 which swing out of the catalytic site upon the binding of trehalose. The
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Figure 4.7. Conformational changes. Shown are ribbon diagrams of the three conformers of
VldE modeled using the VldE•GDP•TRE crystallographic data. Residues/molecules of interest
are represented in stick models. Arrows indicate the direction of residue movement. Ligands
bound within each conformer are shown to provide a point of reference for comparison. (A-C)
The global conformation of each conformer (gray) is shown with the areas of conformational
change highlighted by coloring (pink, blue, cyan). (D-F) Residues 11-50 for each conformer is
shown. Note that this region of residues is capable of 10.9Å shift towards the catalytic center
and that strands of the -hairpin motif (2 and 3) move simultaneously with strands 6 and 5
to extend the core -sheet from ten to twelve strands. (G-I) A view of helix 3 for each
conformer is shown. Note that residues at the kink of the helix are capable of reorganizing.
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second and third conformers have only GDP within the catalytic site and both of these
conformers share a dramatic shift in residues 11-50 which result in the “closing” of the catalytic
site (Figure 4.7D-F). Resultantly, Gly33, Gly34, and Thr35 move 10.9Å towards the catalytic
center, and within 4Å of the ligand atoms. Additionally, helix , which originally consisted of
residues 36-41, coils further to include residues 42-47. This shift occurs concurrently with the
rotation of the -hairpin motif (2 and 3) unique to VldE. Additionally, the last two of ten
strands (6 and 5) comprising the core -sheet of the N-terminal Rossman-like // domain
move towards the compacting catalytic site. The movements of the unique -hairpin motif and
the two strands of the core -sheet narrow the distance between them and allow the necessary
interactions to unite them into a single twelve-stranded core -sheet. The “closed”
conformation described here is similar to what was described in the structural study of
ValL.(Zheng, Zhou et al. 2012)
A conformational change which resulted in the closing of the catalytic site was described
within the structural studies of OtsA. Residues were observed to make a >10Å movement
towards the catalytic center upon binding of the accepting sugar in OtsA.(Gibson, Turkenburg et
al. 2002; Gibson, Tarling et al. 2004) The conformational shift was thought to be due to the
recognition of the phosphate moiety of the accepting glucose 6-phosphate by Arg9. However,
with the lack of an acceptor group within the catalytic site, the conserved arginine at position 12
of VldE cannot be responsible for the closing of the catalytic site. Therefore, the closing of the
VldE catalytic site is more likely to work at least partially through a more dynamic, equilibrium
based mechanism.
An additional conformation change was also observed within the third conformer found
within the VldE•GDP•TRE crystal (Figure 4.7G-I). Within the 3, there is a kink at residues 96100

102. Within the third conformer, the kinked residues shift to form a more organized secondary
structure. Again, the observed conformational change is not concerted with the binding of ligand
and further supports the notion that VldE moves through equilibrium based conformations.
Conformational change at this position was observed in the previous structural studies, and
similarly the change seems to be focused around Gln96.(Zheng, Zhou et al. 2012)

Discussion
Mechanistic Considerations
The net retention of the anomeric center is thought to occur through either a double
displacement (SN2 X2) or internal return mechanism (SNi).(Lairson, Henrissat et al. 2008)
Recent evidence substantiates claims that the conservation of the anomeric center configuration
within OtsA is due to an internal return mechanism.(Errey, Lee et al. 2010; Lee, Hong et al.
2011) If the reaction of VldE were to alternatively go through a double displacement
nucleophilic substitution mechanism, a residue must be available to make a covalent
intermediate. Comparatively, the hydrolysis of glycosides is known to occur through a
nucleophilic substitution involving a covalent intermediate.(Tews, Perrakis et al. 1996; Vocadlo,
Davies et al. 2001) The most likely candidate residue within VldE would be a nucleophilic
His182. As can be seen in Figure 4.4D, this residue is also conserved within the catalytic site of
OtsA (His154). At a 5.1Å from the anomeric center, His182 is not observed to be immediately
available for nucleophilic substitution in our structural studies, and as of yet there has been no
significant, direct evidence to support a mechanism by which the non-glycosidic coupling
reaction of VldE occurs through a covalent intermediate.
Our structural evidence demonstrates a strict conservation of nucleotide and cyclitol
orientation within VldE and OtsA and suggests that the glycosyltransferase reaction of OtsA and
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the pseudo-glycosyltransferase reaction of VldE do occur through similar, concerted but
asynchronous internal return mechanisms. Therefore, the olefinic moiety of GDP-valienol must
play a critical role in facilitating the coupling reaction through a mechanism similar to the
formation of an oxocarbenium ion within OtsA as was previously suggested (Asamizu, Yang et
al. 2011). Through such a mechanism, the transition state is formed by the coordination of the
allylic carbon on donated cyclitol, the bridging amine of the acceptor cyclitol-phosphate and the
leaving oxygen of the donor diphosphate-nucleotide. As in OtsA (Errey, Lee et al. 2010), the
leaving phosphate is in a position to deprotonate the incoming nucleophile of the acceptor
cyclitol (Figure 4.8A-B).
Supportively, a distance matrix search using DALI (Holm and Rosenstrom 2010)
revealed a strong similarity between VldE and OtsA, cetyl--D-Glucosaminyl L-Malate
Synthase (BaBshA), 3-Phospho-1-D-I-Inosityl-2-Acetamido-2-Deoxy--D-Glucopyranoside
Synthase (MshA), Trehalose Synthase (TreT), Phosphatidylinositol Mannosyltransferase
(PimA), and Glycogen Synthase (GlgA). (Table 4.3) All are retaining glycosyltransferases that
have been associated with internal return mechanisms.(Horcajada, Guinovart et al. 2006;
Vetting, Frantom et al. 2008; Batt, Jabeen et al. 2010; Errey, Lee et al. 2010; Parsonage, Newton
et al. 2010; Woo, Ryu et al. 2010) (Table 4.3)
Significance
The biosynthetic pathways of natural products exhibiting antibiotic-like properties have recently
become of great interest. As seen in the discovery of the antibacterial erythromycin, the
anthelmintic avermectins, and the antitumor indolocarbozes, the genetic manipulation of
biosynthetic gene clusters along with the use of alternative biosynthetic precursors, and
recombinant proteins for chemoenzymatic synthesis can result in the generation of an entire
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Figure 4.8. The SNi mechanism of VldE. Shown are ChemBioDraw figures comparing the SNi
mechanism of (A) OtsA to the proposed SNi mechanism of (B) VldE. The olefinic moiety of
GDP-valienol plays a critical role in facilitating the coupling reaction through a mechanism
similar to the formation of an oxocarbenium ion within OtsA. Both transition states are formed
by the coordination of the allylic carbon on the donated group, the bridging nucleophile of the
acceptor group and the leaving oxygen of the donor diphosphate-nucleotide.

Table 4.3. DALI server results
Enzyme Name
Trehalose-Phosphate Synthase (OtsA)

cetyl--D-Glucosaminyl L-Malate Synthase
(BaBshA)

R.M.S.D
2.4
2.9

3-Phospho-1-D-I-Inosityl-2-Acetamido-2-Deoxy-D-Glucopyranoside Synthase (MshA)

3.7

Trehalose Synthase (TreT)

3.1

Phosphatidylinositol Mannosyltransferase (PimA)

3.1

Glycogen Synthase (GlgA)

3.1

- Listed in order of DALI ranking
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array of biologically active compounds.(McDaniel, Thamchaipenet et al. 1999; Cropp, Wilson et
al. 2000; Sanchez, Mendez et al. 2006; Mahmud, Flatt et al. 2007) The gene cluster responsible
for the biosynthesis of validamycin A has only been recently discovered, this study and others
are underway to elucidate the individual processes within this biosynthetic pathway of this C7Naminocyclitol.(Bai, Li et al. 2006)
The C7N-aminocyclitols (e.g., acarbose, validamycin, cetoniacytone, and salbostatin)
belong to a class of natural products which include the aminoglycosides (e.g., streptomycin,
hygromycin, butirosin, and neomycin), and the five membered aminocyclitols or cyclopentitols
(e.g., pactamycin, trehazolin, and allosamidin). The aminoglycosides are a diverse group of
natural products which were amongst the first clinical antibiotics. The C7N-aminocyclitols are
an even more diverse group of natural products with an entire range of biological
activities.(Mahmud 2009) A better understanding of the biosynthesis of C7N-aminocyclitols at
the molecular level could allow for the generation of novel, natural product analogs which could
include an array of structurally altered antibiotics. The line of inquiry provided within this
article hopes to add to that understanding.
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CHAPTER 5: CONCLUSIONS
As it is a technique that allows for the elucidation of structural information of a target
molecule at the atomic level, protein crystallography is an extremely powerful tool. The threedimensional graphics of proteins produced by crystallographers allows for the illustration of
bonding networks and the differentiation of closely related isoenzymes. Crystallographic studies
can also explain substrate specificity and provide insight, support, or validation to the underlying
chemistry of a catalytic mechanism. This work describes the use of x-ray crystallography in
exactly such a manner. Protein crystallography was put to use in the examination of the protein
enzymes, PFKB3 and VldE.
The bifunctional enzyme is solely responsible for the cellular concentrations of an
effector of glucose metabolism, fructose-2,6-bisphosphate. The inducible isoform has been
implicated in the “Warburg Effect” in cancer biology and is unique because of a high
bisphosphatase/kinase ratio. However, the low bisphosphatase activity of PFKFB3 allowed for a
unique opportunity to study the bisphosphatase reaction. Although the experiments described
within this work are not the first crystallographic studies of PFKB3 (Kim, Manes et al. 2006;
Kim, Cavalier et al. 2007), much insight was still obtained from this study. As previously
described the degradation of fructose-2,6-bisphosphate is mediated through a mechanism typical
of members of the histidine phosphatase family (Rigden 2008). The reaction begins with the
nucleophilic attack by a catalytic histidine which forms a phospho-histidine intermediate. The
residue side-chains forming the phosphate pocket stay in contact with the phosphate oxygens
during the entirety of the reaction. There is a linear transfer of phosphate to the histidine and a
catalytic side-chain acts as a general acid/base in the facilitation of the leaving fructose-6phosphate and in the activation of a water molecule for the degradation of the phospho-histidine
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intermediate. This study provided the last experimental data necessary to provide a complete
visualization of catalysis from binding of substrate within the Michaelis complex through the
transition states to the release of products. Also reported is a novel conformational change in the
C-terminal residues which suggests a role in substrate/product binding /release. Hopefully these
observations could provide insight to other researchers investigating other histidine phosphatase
family members.
The crystallographic studies of VldE reveal an enzyme with a global fold typical of GT-B
glycosyltransferases that markedly generates a non-glycosidic bond. Furthermore, catalysis
seems to be mediated by an internal return mechanism that has been associated with many
glycosyltransferases which allows for the retention of the anomeric configuration of the donated
moiety (Lairson, Henrissat et al. 2008). The preference of this glycosyltransferase family
member for GDP as the activating nucleotide is clearly explained by the selective hydrogen bond
network within the catalytic site. These structural studies provide the next step in the
understanding of the validamycin biosynthetic pathway and can provide insight into the synthesis
of other C7N containing natural products. Additionally, understanding of the molecular basis of
catalysis by VldE could directly lead to efforts of scaffold diversification of validamycin for
pharmacophoric optimization of anti-biotics with potential clinical significance through the
genetic manipulation of the biosynthetic gene cluster, the use of alternative biosynthetic
precursors, or the use of recombinant proteins.
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APPENDIXES
A. A Crystallographic Study
X-ray crystallography is a form of very high resolution microscopy that allows researchers to
generate a three-dimensional structure of a protein and is one of the few techniques that can
provide information regarding the catalytic site at the atomic, or near- atomic, level. This
technique is implemented by growing a crystal comprised entirely of protein and then exposing it
to an x-ray source. The diffracted x-rays are then measured and used to interpret the position of
each atom in three-dimensional space. Once the positions of the protein atoms are calculated,
researchers can investigate the interactions between the protein and its bound ligands. This
information can explain how ligands influence a protein and which amino acids are involved in
their binding. The specific amino acids involved in catalysis can also be identified.
Furthermore, x-ray crystallography can be used to support or explain the observations made in
kinetic and functional studies of enzymes.
Within this document, x-ray crystallography was used to investigate the catalysis performed
by the enzymes, PFKFB3 and VldE. Using this technique, the intermediates of the PFKFB3
reaction were successfully visualized and the catalytic mechanism responsible for the retention
of the stereochemical configuration within VldE products was elucidated. X-ray crystallography
allowed a visual interpretation of these two reactions which would be otherwise unattainable.
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